Nadia Harbeck

Nadia Harbeck's AcademicInfluence.com Rankings

Nadia Harbeck

Biology

#5293

World Rank

#7740

Historical Rank

Molecular Biology

#463

World Rank

#472

Historical Rank

Genetics

#476

World Rank

#547

Historical Rank

biology Degrees

Download Badge

Biology

Why Is Nadia Harbeck Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Nadia Harbeck's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Palbociclib and Letrozole in Advanced Breast Cancer. (2016) (1641)
2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial (2007) (1499)
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. (2016) (1176)
Pembrolizumab for Early Triple-Negative Breast Cancer. (2020) (929)
Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. (2010) (855)
Breast cancer (2019) (849)
4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)† (2018) (820)
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer (2018) (674)
3rd ESO-ESMO international consensus guidelines for Advanced Breast Cancer (ABC 3). (2017) (661)
De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017 (2018) (639)
Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer. (2015) (634)
Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. (2002) (619)
National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. (2008) (603)
Breast cancer (2017) (601)
ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)† (2014) (566)
Triple-negative breast cancer--current status and future directions. (2009) (560)
5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) (529)
Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer. (2019) (527)
Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. (2018) (518)
Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups. (2011) (472)
Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1. (2001) (471)
Clinical Impact of the Plasminogen Activation System in Tumor Invasion and Metastasis: Prognostic Relevance and Target for Therapy (1997) (427)
Rac1 in human breast cancer: overexpression, mutation analysis, and characterization of a new isoform, Rac1b (2000) (419)
Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial (2020) (416)
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3) (2017) (405)
Clinical use of biomarkers in breast cancer: Updated guidelines from the European Group on Tumor Markers (EGTM). (2017) (373)
Multicenter validation of a gene expression-based prognostic signature in lymph node-negative primary breast cancer. (2006) (369)
De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. (2018) (353)
Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood–brain barrier (2007) (336)
Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial. (2016) (317)
1st International consensus guidelines for advanced breast cancer (ABC 1). (2012) (308)
Cancer progression and tumor cell motility are associated with the FGFR4 Arg(388) allele. (2002) (278)
Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2−, Node-Positive, High-Risk, Early Breast Cancer (monarchE) (2020) (274)
Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial. (2018) (269)
The European Society of Breast Cancer Specialists recommendations for the management of young women with breast cancer. (2012) (265)
C‐Met overexpression in node‐positive breast cancer identifies patients with poor clinical outcome independent of Her2/neu (2005) (261)
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer. (2022) (260)
Prognosis of women with primary breast cancer diagnosed during pregnancy: results from an international collaborative study. (2013) (248)
Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials (2010) (247)
West German Study Group Phase III PlanB Trial: First Prospective Outcome Data for the 21-Gene Recurrence Score Assay and Concordance of Prognostic Markers by Central and Local Pathology Assessment. (2016) (242)
Spatial and temporal regulation of gap junction connexin43 in vascular endothelial cells exposed to controlled disturbed flows in vitro. (1999) (242)
Management of venous port systems in oncology: a review of current evidence. (2008) (237)
Trastuzumab emtansine (T-DM1) renders HER2+ breast cancer highly susceptible to CTLA-4/PD-1 blockade (2015) (236)
Randomized, double-blind, placebo-controlled, phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer (mBC): AVADO. (2008) (227)
Treatment of breast cancer during pregnancy: an observational study. (2012) (226)
Tumour cell detection in the bone marrow of breast cancer patients at primary therapy: results of a 3-year median follow-up. (1994) (226)
Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n = 3424). (2002) (218)
Monitoring primary systemic therapy of large and locally advanced breast cancer by using sequential positron emission tomography imaging with [18F]fluorodeoxyglucose. (2009) (211)
ESO-ESMO 3rd international consensus guidelines for breast cancer in young women (BCY3). (2017) (210)
uPA and PAI-1 as biomarkers in breast cancer: validated for clinical use in level-of-evidence-1 studies (2014) (209)
3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3). (2016) (208)
PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in breast cancer. (2015) (204)
ESO-ESMO 2 nd international consensus guidelines for advanced breast cancer ( ABC 2 ) (2014) (201)
St. Gallen 2011: Summary of the Consensus Discussion (2011) (199)
Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials (2019) (197)
Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer (2010) (193)
Qualitative and quantitative assessment of taste and smell changes in patients undergoing chemotherapy for breast cancer or gynecologic malignancies. (2009) (192)
Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up (2019) (192)
Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptor–Positive Metastatic Breast Cancer (2019) (188)
Y‐box factor YB‐1 predicts drug resistance and patient outcome in breast cancer independent of clinically relevant tumor biologic factors HER2, uPA and PAI‐1 (2002) (187)
Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase III study. (2010) (186)
Trastuzumab beyond progression: overall survival analysis of the GBG 26/BIG 3-05 phase III study in HER2-positive breast cancer. (2011) (183)
Second international consensus guidelines for breast cancer in young women (BCY2). (2014) (179)
Palbociclib in Combination With Fulvestrant in Women With Hormone Receptor-Positive/HER2-Negative Advanced Metastatic Breast Cancer: Detailed Safety Analysis From a Multicenter, Randomized, Placebo-Controlled, Phase III Study (PALOMA-3). (2016) (176)
Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer (2005) (176)
Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021 (2021) (175)
Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European Panel. (2016) (170)
Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer. (2022) (164)
Dual Targeting of HER2-Positive Cancer with Trastuzumab Emtansine and Pertuzumab: Critical Role for Neuregulin Blockade in Antitumor Response to Combination Therapy (2013) (159)
Disease course patterns after discontinuation of bevacizumab: pooled analysis of randomized phase III trials. (2011) (158)
Patterns of αvβ3 Expression in Primary and Metastatic Human Breast Cancer as Shown by 18F-Galacto-RGD PET (2008) (157)
Urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1: novel tumor-derived factors with a high prognostic and predictive impact in breast cancer (2004) (156)
The 76-gene signature defines high-risk patients that benefit from adjuvant tamoxifen therapy (2009) (151)
Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial. (2021) (150)
ESO-ESMO 4rd International Consensus Guidelines for Breast Cancer in Young Women (BCY4). (2020) (149)
Hydroxamate-type matrix metalloproteinase inhibitor batimastat promotes liver metastasis. (2001) (149)
Human kallikrein 5: a potential novel serum biomarker for breast and ovarian cancer. (2003) (143)
A Brief Summary of the Consensus Discussion (2015) (142)
Clinical relevance of invasion factors urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 for individualized therapy decisions in primary breast cancer is greatest when used in combination. (2002) (140)
Ten-year analysis of the prospective multicentre Chemo-N0 trial validates American Society of Clinical Oncology (ASCO)-recommended biomarkers uPA and PAI-1 for therapy decision making in node-negative breast cancer patients. (2013) (140)
Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial (2017) (139)
Detection and clinical implications of early systemic tumor cell dissemination in breast cancer. (2003) (138)
Intensive dose-dense compared with conventionally scheduled preoperative chemotherapy for high-risk primary breast cancer. (2009) (136)
FGFR4 Arg388 allele is associated with resistance to adjuvant therapy in primary breast cancer. (2006) (133)
Phase III study of taselisib (GDC-0032) + fulvestrant (FULV) v FULV in patients (pts) with estrogen receptor (ER)-positive, PIK3CA-mutant (MUT), locally advanced or metastatic breast cancer (MBC): Primary analysis from SANDPIPER. (2018) (132)
Prognostic significance of urokinase (uPA) and its inhibitor PAI-1 for survival in advanced ovarian carcinoma stage FIGO IIIc (1999) (131)
Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2012) (130)
Quality of life with palbociclib plus fulvestrant in previously treated hormone receptor-positive, HER2-negative metastatic breast cancer: patient-reported outcomes from the PALOMA-3 trial (2016) (128)
PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel and CMF versus a standard-dosed epirubicin/cyclophosphamide followed by paclitaxel ± darbepoetin alfa in primary breast cancer--results at the time of surgery. (2011) (127)
Association of DNA methylation of phosphoserine aminotransferase with response to endocrine therapy in patients with recurrent breast cancer. (2005) (127)
First international consensus guidelines for breast cancer in young women (BCY1). (2014) (124)
The urokinase plasminogen activator system as a novel target for tumour therapy (2000) (122)
St. Gallen 2013: Brief Preliminary Summary of the Consensus Discussion (2013) (120)
Prognostic impact of proteolytic factors (urokinase-type plasminogen activator, plasminogen activator inhibitor 1, and cathepsins B, D, and L) in primary breast cancer reflects effects of adjuvant systemic therapy. (2001) (120)
PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel, and CMF versus a standard-dosed epirubicin-cyclophosphamide followed by paclitaxel with or without darbepoetin alfa in primary breast cancer--outcome on prognosi (2011) (116)
Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): an open-label, randomised, phase 3 trial. (2016) (115)
St. Gallen/Vienna 2019: A Brief Summary of the Consensus Discussion on the Optimal Primary Breast Cancer Treatment (2019) (114)
DNA-methylation of the homeodomain transcription factor PITX2 reliably predicts risk of distant disease recurrence in tamoxifen-treated, node-negative breast cancer patients--Technical and clinical validation in a multi-centre setting in collaboration with the European Organisation for Research and (2007) (113)
Neoadjuvant Trastuzumab Emtansine and Pertuzumab in Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Three-Year Outcomes From the Phase III KRISTINE Study (2019) (110)
KEYNOTE-119: Phase III study of pembrolizumab (pembro) versus single-agent chemotherapy (chemo) for metastatic triple negative breast cancer (mTNBC) (2019) (110)
Invasion factors uPA/PAI-1 and HER2 status provide independent and complementary information on patient outcome in node-negative breast cancer. (2003) (109)
Urokinase-type plasminogen activator and its inhibitor type 1 predict disease outcome and therapy response in primary breast cancer. (2004) (108)
The path to a better biomarker: application of a risk management framework for the implementation of PD‐L1 and TILs as immuno‐oncology biomarkers in breast cancer clinical trials and daily practice (2020) (108)
Triple-negative high-risk breast cancer derives particular benefit from dose intensification of adjuvant chemotherapy: results of WSG AM-01 trial. (2008) (107)
PALOMA-2: Primary results from a phase III trial of palbociclib (P) with letrozole (L) compared with letrozole alone in postmenopausal women with ER+/HER2– advanced breast cancer (ABC). (2016) (105)
RNA Sequencing to Predict Response to Neoadjuvant Anti-HER2 Therapy: A Secondary Analysis of the NeoALTTO Randomized Clinical Trial (2017) (105)
Analysis of the DPYD Gene Implicated in 5-Fluorouracil Catabolism in a Cohort of Caucasian Individuals (2005) (105)
Epigenome-based cancer risk prediction: rationale, opportunities and challenges (2018) (104)
St. Gallen/Vienna 2017: A Brief Summary of the Consensus Discussion about Escalation and De-Escalation of Primary Breast Cancer Treatment (2017) (104)
uPA and PAI-1 in breast cancer: review of their clinical utility and current validation in the prospective NNBC-3 trial. (2008) (103)
The Patient's Anastrozole Compliance to Therapy (PACT) Program: a randomized, in-practice study on the impact of a standardized information program on persistence and compliance to adjuvant endocrine therapy in postmenopausal women with early breast cancer. (2013) (102)
Multicenter study using paraffin-embedded tumor tissue testing PITX2 DNA methylation as a marker for outcome prediction in tamoxifen-treated, node-negative breast cancer patients. (2008) (100)
Enhancing global access to cancer medicines (2020) (100)
DNA hypermethylation of PITX2 is a marker of poor prognosis in untreated lymph node-negative hormone receptor-positive breast cancer patients (2008) (99)
Impact of palbociclib plus letrozole on patient-reported health-related quality of life: results from the PALOMA-2 trial (2018) (97)
Palbociclib Combined with Fulvestrant in Premenopausal Women with Advanced Breast Cancer and Prior Progression on Endocrine Therapy: PALOMA-3 Results. (2017) (97)
Biomarker Analyses of Response to Cyclin-Dependent Kinase 4/6 Inhibition and Endocrine Therapy in Women with Treatment-Naïve Metastatic Breast Cancer (2019) (97)
13th St. Gallen International Breast Cancer Conference 2013: Primary Therapy of Early Breast Cancer Evidence, Controversies, Consensus - Opinion of a German Team of Experts (Zurich 2013) (2013) (97)
DNA Methylation Markers Predict Outcome in Node-Positive, Estrogen Receptor-Positive Breast Cancer with Adjuvant Anthracycline-Based Chemotherapy (2009) (97)
St. Gallen/Vienna 2015: A Brief Summary of the Consensus Discussion (2015) (96)
Risk-group discrimination in node-negative breast cancer using invasion and proliferation markers: 6-year median follow-up (1999) (96)
HER2 Dimerization Inhibitor Pertuzumab - Mode of Action and Clinical Data in Breast Cancer (2013) (95)
Trastuzumab emtansine in human epidermal growth factor receptor 2-positive metastatic breast cancer: an integrated safety analysis. (2014) (94)
Human kallikrein 8, a novel biomarker for ovarian carcinoma. (2003) (94)
Clinical Portrait of the SARS-CoV-2 Epidemic in European Patients with Cancer (2020) (93)
Neoadjuvant Therapy for HER2-positive Breast Cancer. (2017) (92)
Lobular breast cancer: Clinical, molecular and morphological characteristics. (2016) (92)
Molecular and protein markers for clinical decision making in breast cancer: today and tomorrow. (2014) (92)
Response and prognosis after neoadjuvant chemotherapy in 1,051 patients with infiltrating lobular breast carcinoma (2014) (90)
VP7-2021: KEYNOTE-522: Phase III study of neoadjuvant pembrolizumab + chemotherapy vs. placebo + chemotherapy, followed by adjuvant pembrolizumab vs. placebo for early-stage TNBC (2021) (90)
Cancer therapy trials employing level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1 (2011) (90)
WSG ADAPT – adjuvant dynamic marker-adjusted personalized therapy trial optimizing risk assessment and therapy response prediction in early breast cancer: study protocol for a prospective, multi-center, controlled, non-blinded, randomized, investigator initiated phase II/III trial (2013) (90)
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3) (2016) (88)
Pooled analysis of prognostic impact of uPA and PAI-1 in breast cancer patients (2003) (87)
Decreased expression of angiogenesis antagonist EFEMP1 in sporadic breast cancer is caused by aberrant promoter methylation and points to an impact of EFEMP1 as molecular biomarker (2009) (86)
nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial (2018) (83)
Dose-dependent change in biomarkers during neoadjuvant endocrine therapy with fulvestrant: results from NEWEST, a randomized Phase II study (2012) (83)
German adjuvant intergroup node-positive study: a phase III trial to compare oral ibandronate versus observation in patients with high-risk early breast cancer. (2013) (83)
Long-term outcome prediction by clinicopathological risk classification algorithms in node-negative breast cancer--comparison between Adjuvant!, St Gallen, and a novel risk algorithm used in the prospective randomized Node-Negative-Breast Cancer-3 (NNBC-3) trial. (2009) (83)
Human kallikrein 13 protein in ovarian cancer cytosols: a new favorable prognostic marker. (2004) (83)
Treatment planning and evaluation of gated radiotherapy in left-sided breast cancer patients using the CatalystTM/SentinelTM system for deep inspiration breath-hold (DIBH) (2016) (82)
Intrathecal trastuzumab (Herceptin) and methotrexate for meningeal carcinomatosis in HER2-overexpressing metastatic breast cancer: a case report. (2008) (81)
Prognostic impact of proliferation-associated factors MIB1 (Ki-67) and S-phase in node-negative breast cancer. (1997) (80)
Interdisciplinary Screening, Diagnosis, Therapy and Follow-up of Breast Cancer. Guideline of the DGGG and the DKG (S3-Level, AWMF Registry Number 032/045OL, December 2017) – Part 1 with Recommendations for the Screening, Diagnosis and Therapy of Breast Cancer (2018) (80)
Comparison of Neoadjuvant Nab-Paclitaxel+Carboplatin vs Nab-Paclitaxel+Gemcitabine in Triple-Negative Breast Cancer: Randomized WSG-ADAPT-TN Trial Results (2018) (79)
Application of intrathecal trastuzumab (Herceptin™) for treatment of meningeal carcinomatosis in HER2-overexpressing metastatic breast cancer (2006) (77)
Recommendations for collection and handling of specimens from group breast cancer clinical trials. (2008) (75)
Comparison of EP2006, a filgrastim biosimilar, to the reference: a phase III, randomized, double-blind clinical study in the prevention of severe neutropenia in patients with breast cancer receiving myelosuppressive chemotherapy (2015) (74)
Interference with the urokinase plasminogen activator system: a promising therapy concept for solid tumours (2001) (73)
ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2). (2014) (73)
Invasion marker PAI‐1 remains a strong prognostic factor after long‐term follow‐up both for primary breast cancer and following first relapse (1999) (72)
Chemotherapy and Post-traumatic Stress in the Causation of Cognitive Dysfunction in Breast Cancer Patients (2017) (72)
Tumor Markers (2003) (72)
A phase II trial to assess efficacy and safety of afatinib in extensively pretreated patients with HER2-negative metastatic breast cancer (2012) (71)
Phase IIa trial of trastuzumab emtansine with pertuzumab for patients with human epidermal growth factor receptor 2-positive, locally advanced, or metastatic breast cancer. (2014) (71)
First-line trastuzumab plus epirubicin and cyclophosphamide therapy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: cardiac safety and efficacy data from the Herceptin, Cyclophosphamide, and Epirubicin (HERCULES) trial. (2010) (70)
Elucidating pretreatment cognitive impairment in breast cancer patients: the impact of cancer-related post-traumatic stress. (2015) (69)
The patched polymorphism Pro1315Leu (C3944T) may modulate the association between use of oral contraceptives and breast cancer risk (2003) (69)
Clinical utility of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 determination in primary breast cancer tissue for individualized therapy concepts. (2002) (68)
West German Study PlanB Trial: Adjuvant Four Cycles of Epirubicin and Cyclophosphamide Plus Docetaxel Versus Six Cycles of Docetaxel and Cyclophosphamide in HER2-Negative Early Breast Cancer. (2019) (68)
De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR− phase II trial efficacy, safety, and predictive markers for 12 weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab ± weekly paclitaxel (2017) (67)
Urokinase induces proliferation of human ovarian cancer cells: characterization of structural elements required for growth factor function (1998) (67)
AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2019 (2019) (67)
High HER2 Expression Correlates with Response to the Combination of Lapatinib and Trastuzumab (2014) (67)
Phase III randomized study of taselisib or placebo with fulvestrant in estrogen receptor-positive, PIK3CA-mutant, HER2-negative, advanced breast cancer: the SANDPIPER trial. (2020) (66)
DNA methylation as a biomarker in breast cancer. (2009) (66)
Human Kallikrein 8 Protein Is a Favorable Prognostic Marker in Ovarian Cancer (2006) (62)
Time-varying prognostic impact of tumour biological factors urokinase (uPA), PAI-1 and steroid hormone receptor status in primary breast cancer. (1997) (62)
CDK4/6 Inhibitors Expand the Therapeutic Options in Breast Cancer: Palbociclib, Ribociclib and Abemaciclib (2019) (61)
Interdisciplinary Screening, Diagnosis, Therapy and Follow-up of Breast Cancer. Guideline of the DGGG and the DKG (S3-Level, AWMF Registry Number 032/045OL, December 2017) – Part 2 with Recommendations for the Therapy of Primary, Recurrent and Advanced Breast Cancer (2018) (61)
Prognostic impact of tumor biological factors on survival in node-negative breast cancer. (1998) (61)
AGO Recommendations for Diagnosis and Treatment of Patients with Advanced and Metastatic Breast Cancer: Update 2013 (2013) (61)
Cathepsin B, plasminogenactivator-inhibitor (PAI-1) and plasminogenactivator-receptor (uPAR) are prognostic factors for patients with non-small cell lung cancer. (2004) (61)
St. Gallen/Vienna 2021: A Brief Summary of the Consensus Discussion on Customizing Therapies for Women with Early Breast Cancer (2021) (60)
COMPliance and Arthralgia in Clinical Therapy: the COMPACT trial, assessing the incidence of arthralgia, and compliance within the first year of adjuvant anastrozole therapy. (2014) (60)
Cardiac safety of trastuzumab in combination with epirubicin and cyclophosphamide in women with metastatic breast cancer: results of a phase I trial. (2004) (60)
Capecitabine monotherapy: review of studies in first-line HER-2-negative metastatic breast cancer. (2012) (60)
Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer (2020) (60)
KEYNOTE-522: Phase III study of pembrolizumab (pembro) + chemotherapy (chemo) vs placebo (pbo) + chemo as neoadjuvant treatment, followed by pembro vs pbo as adjuvant treatment for early triple-negative breast cancer (TNBC) (2019) (58)
Research needs in breast cancer (2016) (57)
Clinical utility of level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1 (2010) (57)
Mastectomy or Breast-Conserving Therapy for Early Breast Cancer in Real-Life Clinical Practice: Outcome Comparison of 7565 Cases (2019) (56)
Immunofluorometric Quantification of Human Kallikrein 5 Expression in Ovarian Cancer Cytosols and Its Association with Unfavorable Patient Prognosis (2003) (56)
Association between HER2, TOP2A, and response to anthracycline-based preoperative chemotherapy in high-risk primary breast cancer (2010) (55)
Long-Term Follow-Up Confirms Prognostic Impact of Pai-1 and Cathepsin D and L in Primary Breast Cancer (2000) (55)
Y-box-binding protein YB-1 identifies high-risk patients with primary breast cancer benefiting from rapidly cycled tandem high-dose adjuvant chemotherapy. (2009) (54)
Report on computational assessment of Tumor Infiltrating Lymphocytes from the International Immuno-Oncology Biomarker Working Group (2020) (54)
Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial (2016) (54)
Does deep inspiration breath-hold prolong life? Individual risk estimates of ischaemic heart disease after breast cancer radiotherapy. (2018) (53)
Clinically assessed posttraumatic stress in patients with breast cancer during the first year after diagnosis in the prospective, longitudinal, controlled COGNICARES study (2017) (53)
Human kallikrein 11: an indicator of favorable prognosis in ovarian cancer patients. (2004) (53)
Correlation of various pathologic complete response (pCR) definitions with long-term outcome and the prognostic value of pCR in various breast cancer subtypes: Results from the German neoadjuvant meta-analysis. (2011) (53)
Differential expression of c‐Met, its ligand HGF/SF and HER2/neu in DCIS and adjacent normal breast tissue (2007) (53)
Meta and pooled analyses of FGFR4 Gly388Arg polymorphism as a cancer prognostic factor (2011) (51)
Urokinase-Type Plasminogen Activator System in Breast Cancer (2004) (51)
Personalized treatment of early-stage breast cancer: present concepts and future directions. (2010) (51)
Prevalence and impact of COVID-19 sequelae on treatment and survival of patients with cancer who recovered from SARS-CoV-2 infection: evidence from the OnCovid retrospective, multicentre registry study (2021) (49)
HER-2/neu gene amplification by fluorescence in situ hybridization allows risk-group assessment in node-negative breast cancer. (1999) (48)
Prospective evaluation of prognostic factors uPA/PAI-1 in node-negative breast cancer: Phase III NNBC3-Europe trial (AGO, GBG, EORTC-PBG) comparing 6 × FEC versus 3 × FEC/3 × Docetaxel (2011) (48)
Reduced Incidence of Severe Palmar-Plantar Erythrodysesthesia and Mucositis in a Prospective Multicenter Phase II Trial with Pegylated Liposomal Doxorubicin at 40 mg/m2 Every 4 Weeks in Previously Treated Patients with Metastatic Breast Cancer (2006) (48)
Abstract GS2-05: First-line ribociclib vs placebo with goserelin and tamoxifen or a non-steroidal aromatase inhibitor in premenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer: Results from the randomized phase III MONALEESA-7 trial (2018) (48)
Clinical Relevance of the Plasminogen Activator Inhibitor Type1 – a Multifaceted Proteolytic Factor (2001) (47)
Clinical feasibility of (neo)adjuvant taxane-based chemotherapy in older patients: analysis of >4,500 patients from four German randomized breast cancer trials (2008) (47)
Evolving psychosocial, emotional, functional, and support needs of women with advanced breast cancer: Results from the Count Us, Know Us, Join Us and Here & Now surveys. (2016) (46)
Palbociclib plus endocrine therapy in older women with HR+/HER2- advanced breast cancer: a pooled analysis of randomised PALOMA clinical studies. (2018) (46)
Expression profiling identifies genes that predict recurrence of breast cancer after adjuvant CMF-based chemotherapy (2009) (46)
Abstract P3-14-01: A Phase Ib/II Trial of Trastuzumab-DM1 with Pertuzumab for Patients with HER2-Positive, Locally Advanced or Metastatic Breast Cancer: Interim Efficacy and Safety Results (2010) (45)
Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expression. (2014) (44)
Pathologic complete response (pCR) rates after neoadjuvant trastuzumab emtansine (T-DM1 [K]) + pertuzumab (P) vs docetaxel + carboplatin + trastuzumab + P (TCHP) treatment in patients with HER2-positive (HER2+) early breast cancer (EBC) (KRISTINE). (2016) (44)
AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2022 (2020) (44)
14th St. Gallen International Breast Cancer Conference 2015: Evidence, Controversies, Consensus - Primary Therapy of Early Breast Cancer: Opinions Expressed by German Experts (2015) (44)
Neoadjuvant therapy for triple negative and HER2-positive early breast cancer. (2017) (44)
Characteristics of the level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1 (2010) (42)
AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2021 (2021) (41)
AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2021 (2021) (41)
Tumor-Associated Proteolytic Factors uPA and PAI-1: Critical Appraisal of Their Clinical Relevance in Breast Cancer and Their Integration into Decision-Support Algorithms (2007) (41)
The role of capecitabine in first-line treatment for patients with metastatic breast cancer. (2006) (41)
Cardiovascular complications of conventional and targeted adjuvant breast cancer therapy. (2011) (41)
Obesity as an independent risk factor for decreased survival in node-positive high-risk breast cancer (2015) (40)
Cardiac biomarkers for early detection and prediction of trastuzumab and/or lapatinib-induced cardiotoxicity in patients with HER2-positive early-stage breast cancer: a NeoALTTO sub-study (BIG 1-06) (2017) (40)
CDO1 Promoter Methylation is a Biomarker for Outcome Prediction of Anthracycline Treated, Estrogen Receptor-Positive, Lymph Node-Positive Breast Cancer Patients (2010) (40)
A Comparison of Proposed Biosimilar LA-EP2006 and Reference Pegfilgrastim for the Prevention of Neutropenia in Patients With Early-Stage Breast Cancer Receiving Myelosuppressive Adjuvant or Neoadjuvant Chemotherapy: Pegfilgrastim Randomized Oncology (Supportive Care) Trial to Evaluate Comparative Tr (2016) (40)
Impact of expression differences of kallikrein-related peptidases and of uPA and PAI-1 between primary tumor and omentum metastasis in advanced ovarian cancer. (2011) (39)
Time-Dependent COVID-19 Mortality in Patients With Cancer: An Updated Analysis of the OnCovid Registry. (2021) (39)
Primary Therapy of Early Breast Cancer: Evidence, Controversies, Consensus (2019) (38)
Circulating biomarker tissue kallikrein-related peptidase KLK5 impacts ovarian cancer patients' survival. (2010) (38)
Afatinib in the treatment of breast cancer (2014) (37)
European Organisation for Research and Treatment of Cancer (EORTC) Pathobiology Group standard operating procedure for the preparation of human tumour tissue extracts suited for the quantitative analysis of tissue-associated biomarkers. (2007) (37)
Procedures for the quantitative protein determination of urokinase and its inhibitor, PAI-1, in human breast cancer tissue extracts by ELISA. (2006) (37)
Anthracycline rechallenge using pegylated liposomal doxorubicin in patients with metastatic breast cancer: a pooled analysis using individual data from four prospective trials (2010) (37)
Randomized, double-blind study comparing proposed biosimilar LA-EP2006 with reference pegfilgrastim in breast cancer (2016) (36)
Final Overall Survival (OS) Results from the Randomised, Double-Blind, Placebo-Controlled, Phase III AVADO Study of Bevacizumab (BV) Plus Docetaxel (D) Compared with Placebo (PL) Plus D for the First-Line Treatment of Locally Recurrent (LR) or Metastatic Breast Cancer (mBC). (2009) (36)
Feasibility of measuring the prognostic factors uPA and PAI-1 in core needle biopsy breast cancer specimens. (2009) (36)
The impact of epoetin-alpha on anemia, red blood cell (RBC) transfusions, and survival in breast cancer patients (pts) treated with dose-dense sequential chemotherapy: Mature results of an AGO phase III study (ETC trial) (2007) (36)
A Web- and App-Based Connected Care Solution for COVID-19 In- and Outpatient Care: Qualitative Study and Application Development (2020) (35)
Identification of low-risk node-negative breast cancer patients by tumor biological factors PAI-1 and cathepsin L. (1998) (35)
Identification, validation, and clinical implementation of tumor-associated biomarkers to improve therapy concepts, survival, and quality of life of cancer patients: tasks of the Receptor and Biomarker Group of the European Organization for Research and Treatment of Cancer. (2004) (35)
Lost in translation? Estrogen receptor status and endocrine responsiveness in breast cancer. (2012) (35)
Influence of patient and tumor characteristics on early therapy persistence with letrozole in postmenopausal women with early breast cancer: results of the prospective Evaluate-TM study with 3941 patients (2018) (35)
De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR- phase II trial: efficacy, safety, and predictive markers for 12weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab ± weekly paclitaxel. (2017) (35)
Advances in targeting HER2-positive breast cancer (2017) (34)
A new look at node-negative breast cancer. (2010) (34)
Improved systemic treatment for early breast cancer improves cure rates, modifies metastatic pattern and shortens post-metastatic survival: 35-year results from the Munich Cancer Registry (2017) (34)
Ten-year results of intense dose-dense chemotherapy show superior survival compared with a conventional schedule in high-risk primary breast cancer: final results of AGO phase III iddEPC trial (2018) (34)
Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial (2015) (34)
Palbociclib with Letrozole in Postmenopausal Women with ER+/HER2− Advanced Breast Cancer: Hematologic Safety Analysis of the Randomized PALOMA‐2 Trial (2019) (33)
Genomic and Transcriptomic Analyses of Breast Cancer Primaries and Matched Metastases in AURORA, the Breast International Group (BIG) Molecular Screening Initiative (2021) (33)
Antibody therapy for breast cancer. (2005) (33)
Overall survival (OS) with palbociclib (PAL) + fulvestrant (FUL) in women with hormone receptor–positive (HR+), human epidermal growth factor receptor 2–negative (HER2–) advanced breast cancer (ABC): Updated analyses from PALOMA-3. (2021) (33)
Application of intrathecal trastuzumab (Herceptintrade mark) for treatment of meningeal carcinomatosis in HER2-overexpressing metastatic breast cancer. (2006) (33)
Abstract PD5-03: Relationship between tumor-infiltrating lymphocytes (TILs) and outcomes in the KEYNOTE-119 study of pembrolizumab vs chemotherapy for previously treated metastatic triple-negative breast cancer (mTNBC) (2020) (32)
St. Gallen 2007: Breast Cancer Treatment Consensus Report (2007) (32)
Everolimus as treatment for breast cancer patients with bone metastases only: results of the phase II RADAR study (2013) (31)
Adjuvant radiotherapy after breast conserving surgery - a comparative effectiveness research study. (2015) (31)
The effect of EUSOMA certification on quality of breast cancer care. (2015) (31)
PALOMA3: A double-blind, phase III trial of fulvestrant with or without palbociclib in pre- and post-menopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer that progressed on prior endocrine therapy. (2015) (31)
AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2019 (2019) (31)
Initial Treatment of Patients with Primary Breast Cancer: Evidence, Controversies, Consensus: Spectrum of Opinion of German Specialists at the 15th International St. Gallen Breast Cancer Conference (Vienna 2017). (2017) (30)
PTK7 expression in triple-negative breast cancer. (2013) (30)
SOLTI NeoPARP: a phase II randomized study of two schedules of iniparib plus paclitaxel versus paclitaxel alone as neoadjuvant therapy in patients with triple-negative breast cancer (2015) (30)
SANDPIPER: Phase III study of the PI3-kinase (PI3K) inhibitor taselisib (GDC-0032) plus fulvestrant in patients (pts) with estrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer (BC) enriched for pts with PIK3CA-mutant tumors. (2016) (30)
Prognostic impact and clinical relevance of tumor associated proteases in breast cancer (1992) (30)
Influence of side-effects on early therapy persistence with letrozole in post-menopausal patients with early breast cancer: Results of the prospective EvAluate-TM study. (2018) (30)
Side Effects of Standard Adjuvant and Neoadjuvant Chemotherapy Regimens According to Age Groups in Primary Breast Cancer (2013) (29)
A phase Ib/II trial of trastuzumab-DM1 (T-DM1) with pertuzumab (P) for women with HER2-positive, locally advanced or metastatic breast cancer (BC) who were previously treated with trastuzumab (T). (2010) (29)
Expected Medium- and Long-Term Impact of the COVID-19 Outbreak in Oncology (2021) (29)
Time trends (2006-2015) of quality indicators in EUSOMA-certified breast centres. (2017) (28)
Primary Tumor Levels of Human Tissue Kallikreins Affect Surgical Success and Survival in Ovarian Cancer Patients (2007) (28)
Oncological care organisation during COVID-19 outbreak (2020) (28)
EHealth Acceptance and New Media Preferences for Therapy Assistance Among Breast Cancer Patients (2016) (28)
Phase III MONALEESA-7 trial of premenopausal patients with HR+/HER2− advanced breast cancer (ABC) treated with endocrine therapy ± ribociclib: Overall survival (OS) results. (2019) (28)
Tumor-Biological Factors Upa and PAI-1 as Stratification Criteria of a Multicenter Adjuvant Chemotherapy Trial in Node-Negative Breast Cancer (2000) (28)
The West German Study Group Breast Cancer Intrinsic Subtype study: a prospective multicenter decision impact study utilizing the Prosigna assay for adjuvant treatment decision-making in estrogen-receptor-positive, HER2-negative early-stage breast cancer (2016) (27)
Increased trace amine-associated receptor 1 (TAAR1) expression is associated with a positive survival rate in patients with breast cancer (2017) (27)
Cost-utility analysis for advanced breast cancer therapy in Germany: results of the fulvestrant sequencing model (2009) (27)
International Consensus Conference for Advanced Breast Cancer, Lisbon 2019: ABC5 Consensus – Assessment by a German Group of Experts (2020) (27)
Effect of platinum-containing chemotherapy on olfactory, gustatory, and hearing function in ovarian cancer patients (2012) (27)
Abstract P2-09-10: Comprehensive gene expression biomarker analysis of CDK 4/6 and endocrine pathways from the PALOMA-2 study (2018) (26)
Abstract P1-11-03: Pathological Complete Response after Neoadjuvant Chemotherapy + Trastuzumab Treatment Predicts Survival and Detects a Patient Subgroup at High Need for Improvement of Anti-HER2 Therapy. Three Year Median Follow-Up Data of the TECHNO Trial (2010) (26)
A Randomized, Double-Blind, Phase II Study of Two Doses of Pemetrexed as First-Line Chemotherapy for Advanced Breast Cancer (2007) (26)
Outcomes of the SARS-CoV-2 omicron (B.1.1.529) variant outbreak among vaccinated and unvaccinated patients with cancer in Europe: results from the retrospective, multicentre, OnCovid registry study (2022) (26)
Health-related quality of life in premenopausal women with hormone-receptor-positive, HER2-negative advanced breast cancer treated with ribociclib plus endocrine therapy: results from a phase III randomized clinical trial (MONALEESA-7) (2020) (26)
A randomized phase III study evaluating pegylated liposomal doxorubicin versus capecitabine as first-line therapy for metastatic breast cancer: results of the PELICAN study (2016) (26)
Survival of de novo stage IV breast cancer patients over three decades (2016) (26)
Assessment of Urokinase-Type Plasminogen Activator and Its Inhibitor PAI-1 in Breast Cancer Tissue: Historical Aspects and Future Prospects (2008) (25)
Updated Overall Survival of Ribociclib plus Endocrine Therapy versus Endocrine Therapy Alone in Pre- and Perimenopausal Patients with HR+/HER2− Advanced Breast Cancer in MONALEESA-7: A Phase III Randomized Clinical Trial (2021) (25)
A New Approach to Phenotyping Disseminated Tumor Cells: Methodological advances and Clinical Implications (2000) (25)
Brain metastases in HER2-overexpressing metastatic breast cancer: Comparative analysis of trastuzumab levels in serum and cerebrospinal fluid. (2006) (25)
The Impact of Age on Quality of Life in Breast Cancer Patients Receiving Adjuvant Chemotherapy: A Comparative Analysis From the Prospective Multicenter Randomized ADEBAR trial (2017) (25)
CDK4/6 inhibitors in HR+/HER2- advanced/metastatic breast cancer: a systematic literature review of real-world evidence studies. (2021) (24)
Prospective Multicenter Randomized Phase III Study of Weekly versus Standard Docetaxel (D2) for First-Line Treatment of Metastatic Breast Cancer (2011) (24)
Central European Cooperative Oncology Group (2010) (24)
Efficacy of deescalated chemotherapy according to PAM50 subtypes, immune and proliferation genes in triple‐negative early breast cancer: Primary translational analysis of the WSG‐ADAPT‐TN trial (2019) (24)
Detection of micrometastatic disease in bone marrow: is it ready for prime time? (2005) (23)
Interleukin-6 trans-signaling is a candidate mechanism to drive progression of human DCCs during clinical latency (2020) (23)
Gustatory and olfactory function in breast cancer patients (2010) (23)
Primary Therapy of Patients with Early Breast Cancer: Evidence, Controversies, Consensus (2015) (23)
Fetal Renal Insufficiency Following Trastuzumab Treatment for Breast Cancer in Pregnancy: Case Report und Review of the Current Literature (2011) (23)
Study participation improves treatment strategies and individual patient care in participating centers. (2006) (22)
Prognostic Impact of Weight Change During Adjuvant Chemotherapy in Patients With High‐Risk Early Breast Cancer: Results From the ADEBAR Study (2018) (22)
Recover your smile: Effects of a beauty care intervention on depressive symptoms, quality of life, and self‐esteem in patients with early breast cancer (2018) (22)
German Adjuvant Intergroup Node-positive Study (GAIN): a phase III trial comparing two dose-dense regimens (iddEPC versus ddEC-PwX) in high-risk early breast cancer patients (2017) (22)
S2-4: GAIN Study: A Phase III Trial To Compare ETC vs. EC-TX and Ibandronate vs. Observation in Patients with Node-Positive Primary Breast Cancer – 1st Interim Efficacy Analysis. (2011) (22)
Systemic pro-inflammatory response identifies patients with cancer with adverse outcomes from SARS-CoV-2 infection: the OnCovid Inflammatory Score (2021) (21)
PD07-06: Adjuvant Chemotherapy with or without Darbepoetin alpha in Node-Positive Breast Cancer: Survival and Quality of Life Analysis from the Prospective Randomized WSG ARA Plus Trial. (2011) (21)
Final results from the prospective phase III WSG-ARA trial: impact of adjuvant darbepoetin alfa on event-free survival in early breast cancer. (2014) (21)
Factors associated with the decline of psychological support in hospitalized patients with cancer (2019) (21)
ERBB2 mRNA Expression and Response to Ado-Trastuzumab Emtansine (T-DM1) in HER2-Positive Breast Cancer (2020) (21)
Strong impact of MammaPrint and BluePrint on treatment decisions in luminal early breast cancer: results of the WSG-PRIMe study (2019) (21)
Health-related quality of life in male breast cancer patients (2012) (21)
Lobular carcinoma in situ and invasive lobular breast cancer are characterized by enhanced expression of transcription factor AP-2β (2018) (21)
Clinical Relevance of CYP2D6 Genetics for Tamoxifen Response in Breast Cancer (2008) (21)
Angiogenesis inhibitors in the management of breast cancer (2010) (21)
Progression-free Survival Outcome Is Independent of Objective Response in Patients With Estrogen Receptor-positive, Human Epidermal Growth Factor Receptor 2-negative Advanced Breast Cancer Treated With Palbociclib Plus Letrozole Compared With Letrozole: Analysis From PALOMA-2. (2019) (21)
BIBW 2992, a novel irreversible EGFR/HER1 and HER2 tyrosine kinase inhibitor, for the treatment of patients with HER2-negative metastatic breast cancer after failure of no more than two prior chemotherapies. (2010) (21)
Micrometastases in bone marrow in patients with breast cancer (1988) (21)
Cost-Effectiveness Analysis of Anastrozole versus Tamoxifen in Adjuvant Therapy for Early-Stage Breast Cancer – A Health-Economic Analysis Based on the 100-Month Analysis of the ATAC Trial and the German Health System (2010) (21)
Abstract S5-03: Final analysis of WSG-ADAPT HER2+/HR+ phase II trial: Efficacy, safety, and predictive markers for 12-weeks of neoadjuvant TDM1 with or without endocrine therapy versus trastuzumab+endocrine therapy in HER2-positive hormone-receptor-positive early breast cancer (2016) (21)
Molecular markers of metastasis in breast cancer: current understanding and prospects for novel diagnosis and prevention (2001) (21)
LUX-breast 1: Randomized, phase III trial of afatinib and vinorelbine versus trastuzumab and vinorelbine in patients with HER2-overexpressing metastatic breast cancer (MBC) failing one prior trastuzumab treatment. (2012) (20)
Differential impact of prognostic parameters in hormone receptor–positive lobular breast cancer (2020) (20)
Endocrine sensitivity is decisive for patient outcome in small node-negative breast cancers (BC) (pT1a,b) - results from the Munich Cancer Registry. (2015) (20)
Influence of vitamin D signaling on hormone receptor status and HER2 expression in breast cancer (2016) (20)
Health economic impact of risk group selection according to ASCO-recommended biomarkers uPA/PAI-1 in node-negative primary breast cancer (2013) (20)
Primary analysis of KAITLIN: A phase III study of trastuzumab emtansine (T-DM1) + pertuzumab versus trastuzumab + pertuzumab + taxane, after anthracyclines as adjuvant therapy for high-risk HER2-positive early breast cancer (EBC). (2020) (20)
Abstract CT039: Cyclin E1 (CCNE1)expression associates with benefit from palbociclib in metastatic breast cancer (MBC) in the PALOMA3 trial (2018) (20)
LBA9BREAST CANCER TREATMENT WITH EVEROLIMUS AND EXEMESTANE FOR ER+ WOMEN - RESULTS OF THE 2ND INTERIM ANALYSIS OF THE NON-INTERVENTIONAL TRIAL BRAWO (2014) (20)
ERBB2 mutation frequency in lobular breast cancer with pleomorphic histology or high‐risk characteristics by molecular expression profiling (2019) (20)
Clinical Relevance of Prognostic Factors in Axillary Node-Negative Breast Cancer (2003) (20)
Timing of radiotherapy following breast-conserving surgery: outcome of 1393 patients at a single institution (2014) (20)
Surgical management of ipsilateral breast tumor recurrence. (2015) (19)
New ELISA for quantitation of human urokinase receptor (CD87) in cancer. (2000) (19)
Insights into biology of luminal HER2 vs. enriched HER2 subtypes: Therapeutic implications. (2015) (19)
Interest in Integrative Medicine Among Postmenopausal Hormone Receptor–Positive Breast Cancer Patients in the EvAluate-TM Study (2016) (19)
Evidence-based guidelines for managing patients with primary ER+ HER2− breast cancer deferred from surgery due to the COVID-19 pandemic (2020) (19)
Stability of person-specific blood-based infrared molecular fingerprints opens up prospects for health monitoring (2021) (19)
Thrombophilic state in breast cancer. (1999) (19)
Neoadjuvant radiotherapy followed by mastectomy and immediate breast reconstruction (2017) (19)
The Prognostic Impact of the Aryl Hydrocarbon Receptor (AhR) in Primary Breast Cancer Depends on the Lymph Node Status (2019) (18)
Efficacy of 12-weeks of neoadjuvant TDM1 with or without endocrine therapy in HER2-positive hormone-receptor-positive early breast cancer: WSG-ADAPT HER2+/HR+ phase II trial. (2015) (18)
Pooled analysis of two randomized phase III trials (PlanB/SuccessC) comparing six cycles of docetaxel and cyclophosphamide to sequential anthracycline taxane chemotherapy in patients with intermediate and high risk HER2-negative early breast cancer (n=5,923). (2018) (18)
Risk estimations and treatment decisions in early stage breast cancer: agreement among oncologists and the impact of the 70-gene signature. (2014) (18)
Corrigendum to "3rd ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 3)" [Breast 31 (February 2017) 244-259]. (2017) (18)
Biomolecular features of clinical relevance in breast cancer (2004) (18)
AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2022 (2022) (18)
Endocrine Therapy Response and 21-Gene Expression Assay for Therapy Guidance in HR+/HER2– Early Breast Cancer (2022) (18)
Safety and efficacy of alternating treatment with EP2006, a filgrastim biosimilar, and reference filgrastim: a phase III, randomised, double-blind clinical study in the prevention of severe neutropenia in patients with breast cancer receiving myelosuppressive chemotherapy (2018) (18)
Abstract GS5-07: International pooled analysis of the prognostic impact of disseminated tumor cells from the bone marrow in early breast cancer: Results from the PADDY study (2019) (18)
Management of Patients with Brain Metastases Receiving Trastuzumab Treatment for Metastatic Breast Cancer (2011) (18)
Prospective WSG phase III PlanB trial: Final analysis of adjuvant 4xEC→4x doc vs. 6x docetaxel/cyclophosphamide in patients with high clinical risk and intermediate-to-high genomic risk HER2-negative, early breast cancer. (2017) (17)
BRCA1‐like profile predicts benefit of tandem high dose epirubicin‐cyclophospamide‐thiotepa in high risk breast cancer patients randomized in the WSG‐AM01 trial (2016) (17)
A retrospective investigation of women’s experience with breast reconstruction after mastectomy (2013) (17)
Phase II trial of vinorelbine and trastuzumab in patients with HER2-positive metastatic breast cancer. A prospective, open label, non-controlled, multicenter phase II trial (to investigate efficacy and safety of this combination chemotherapy) (2009) (17)
Abstract GS5-03: Lifestyle Intervention and Effect on Disease-free Survival in Early Breast Cancer Pts: Interim Analysis from the Randomized SUCCESS C Study (2019) (17)
LKB1 pro‐oncogenic activity triggers cell survival in circulating tumor cells (2017) (17)
Evidence-based guidelines for managing patients with primary ER+ HER2− breast cancer deferred from surgery due to the COVID-19 pandemic (2020) (17)
Letrozole in Combination with Trastuzumab Is Superior to Letrozole Monotherapy as First Line Treatment in Patients with Hormone-Receptor-Positive, HER2- Positive Metastatic Breast Cancer (MBC) – Results of theeLEcTRATrial. (2009) (17)
PITX2 DNA-methylation predicts response to anthracycline-based adjuvant chemotherapy in triple-negative breast cancer patients (2018) (17)
NEWEST: a Phase II, randomised, neoadjuvant trial comparing fulvestrant 500 mg vs 250 mg in postmenopausal women with locally advanced, oestrogen receptor-positive (ER+) breast cancer (2008) (17)
Abstract P5-21-03: Palbociclib (PAL) + letrozole (LET) as first-line therapy in estrogen receptor–positive (ER+)/human epidermal growth factor receptor 2–negative (HER2−) advanced breast cancer (ABC): Efficacy and safety updates with longer follow-up across patient subgroups (2018) (16)
Comparative Analysis Between the HER2 Status in Primary Breast Cancer Tissue and the Detection of Isolated Tumor Cells in the Bone Marrow (2004) (16)
Overall Survival with Palbociclib and Fulvestrant in Women with HR+/HER2− ABC: Updated Exploratory Analyses of PALOMA-3, a Double-blind, Phase III Randomized Study (2022) (16)
The patient experience (2007) (16)
Heart sparing radiotherapy in breast cancer: the importance of baseline cardiac risks (2020) (16)
Abstract PD2-04: Updated overall survival (OS) results from the phase III MONALEESA-7 trial of pre- or perimenopausal patients with hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2−) advanced breast cancer (ABC) treated with endocrine therapy (ET) ± ribociclib (2021) (16)
Targeted Therapy in Metastatic Breast Cancer: The HER2/neu Oncogene (2010) (15)
Abstract P4-22-06: Treatment postprogression in women with endocrine-resistant HR+/HER2- advanced breast cancer who received palbociclib plus fulvestrant in PALOMA-3 (2017) (15)
Final 10-year analysis of prospective multicenter Chemo N0 trial for validation of ASCO-recommended biomarkers uPA/PAI-1 for therapy decision making in node-negative breast cancer. (2009) (15)
German, Austrian and Swiss consensus conference on the diagnosis and local treatment of the axilla in breast cancer. (2013) (15)
Role of postoperative radiotherapy in reducing ipsilateral recurrence in DCIS: an observational study of 1048 cases (2018) (15)
Pooled analysis of two randomized, double-blind trials comparing proposed biosimilar LA-EP2006 with reference pegfilgrastim in breast cancer (2017) (15)
Prospective WSG phase III PlanB trial: Clinical outcome at 5 year follow up and impact of 21 Gene Recurrence Score result, central/local-pathological review of grade, ER, PR and Ki67 in HR+/HER2-high risk node-negative and -positive breast cancer (2016) (15)
Event-free survival by residual cancer burden after neoadjuvant pembrolizumab + chemotherapy versus placebo + chemotherapy for early TNBC: Exploratory analysis from KEYNOTE-522. (2022) (15)
Immune cell composition and functional marker dynamics from multiplexed immunohistochemistry to predict response to neoadjuvant chemotherapy in the WSG-ADAPT-TN trial (2021) (15)
EP3 (prostaglandin E2 receptor 3) expression is a prognostic factor for progression-free and overall survival in sporadic breast cancer (2018) (15)
Anthracycline and trastuzumab in breast cancer treatment. (2004) (15)
Immunohistochemical demonstration of the zinc metalloprotease insulin-degrading enzyme in normal and malignant human breast: correlation with tissue insulin levels. (2007) (14)
Progression-specific genes identified in microdissected formalin-fixed and paraffin-embedded tissue containing matched ductal carcinoma in situ and invasive ductal breast cancers (2018) (14)
De-escalated neoadjuvant pertuzumab+trastuzumab with or without paclitaxel weekly in HR-/HER2+ early breast cancer: ADAPT-HR-/HER2+ biomarker and survival results. (2021) (14)
A randomized phase III study evaluating pegylated liposomal doxorubicin (PLD) versus capecitabine (CAP) as first-line therapy for metastatic breast cancer (MBC): Results of the PELICAN study. (2010) (14)
Association of p27 and Cyclin D1 Expression and Benefit from Adjuvant Trastuzumab Treatment in HER2-Positive Early Breast Cancer: A TransHERA Study (2018) (14)
Abstract PD2-01: High Ki-67 as a biomarker for identifying patients with high risk early breast cancer treated in monarchE (2021) (14)
S4-3: Prospective Comparison of Risk Assessment Tools in Early Breast Cancer (Recurrence Score, uPA/PAI-1, Central Grade, and Luminal Subtypes): Final Correlation Analysis from the Phase III WSG-Plan B Trial. (2011) (14)
Predictive role of HER2/neu, topoisomerase-II-alpha, and tissue inhibitor of metalloproteinases (TIMP-1) for response to adjuvant taxane-based chemotherapy in patients with intermediate-risk breast cancer: results from the WSG-AGO EC-Doc trial (2015) (14)
Breast cancer is a systemic disease optimally treated by a multidisciplinary team (2020) (14)
A Randomized, Open-label, Presurgical, Window-of-Opportunity Study Comparing the Pharmacodynamic Effects of the Novel Oral SERD AZD9496 with Fulvestrant in Patients with Newly Diagnosed ER+ HER2− Primary Breast Cancer (2020) (14)
Cost Analysis Comparing an Anthracycline/Docetaxel Regimen to CMF in Patients with Early Stage Breast Cancer (2009) (14)
Superiority of sequential docetaxel over standard FE100C in patients with intermediate risk breast cancer: survival results of the randomized intergroup phase III trial EC-Doc. (2009) (14)
LBA11 IMpassion031: Results from a phase III study of neoadjuvant (neoadj) atezolizumab + chemotherapy in early triple-negative breast cancer (TNBC) (2020) (14)
Recent Developments in Radiation Oncology: An Overview of Individualised Treatment Strategies in Breast Cancer (2018) (14)
The WID-BC-index identifies women with primary poor prognostic breast cancer based on DNA methylation in cervical samples (2022) (14)
[Evidence-based recommendations on primary treatment of carcinomas of the breast]. (2002) (14)
Prospective Biomarker Trials Chemo N0 and NNBC-3 Europe Validate the Clinical Utility of Invasion Markers uPA and PAI-1 in Node-Negative Breast Cancer (2008) (13)
Comparison of prognostic and predictive impact of genomic or central grade and immunohistochemical subtypes or IHC4 in HR+/HER2- early breast cancer: WSG-AGO EC-Doc Trial. (2016) (13)
Induction of apoptosis in breast cancer cells in vitro by Fas ligand reverse signaling (2017) (13)
Preclinical and clinical development of afatinib: a focus on breast cancer and squamous cell carcinoma of the head and neck. (2014) (13)
OVSCORE - a validated score to identify ovarian cancer patients not suitable for primary surgery (2014) (13)
Underfinancing of 90.3% for Implant Costs of Prostheses and Expanders in DRG Revenues for Uni- and Bilateral Mastectomy with Immediate Breast Reconstruction (2010) (13)
PTK7 as a potential prognostic and predictive marker of response to adjuvant chemotherapy in breast cancer patients, and resistance to anthracycline drugs (2014) (13)
Endometrial effects of exemestane compared to tamoxifen within the Tamoxifen Exemestane Adjuvant Multicenter (TEAM) trial: results of a prospective gynecological ultrasound substudy. (2010) (13)
Web-/APP-based connected care solution for COVID-19 in- and outpatient care. (2020) (13)
Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial. (2022) (13)
Thyronamine regulation of TAAR1 expression in breast cancer cells and investigation of its influence on viability and migration (2019) (13)
The run-in phase of the prospective WSG-ADAPT HR+/HER2– trial demonstrates the feasibility of a study design combining static and dynamic biomarker assessments for individualized therapy in early breast cancer (2020) (13)
Neural Network Analysis of Follow-Up Data in Primary Breast Cancer (2000) (13)
ABC3 Consensus: Assessment by a German Group of Experts (2016) (13)
Heterogeneity of bone metastases as an important prognostic factor in patients affected by oestrogen receptor-positive breast cancer. The role of combined [18F]Fluoroestradiol PET/CT and [18F]Fluorodeoxyglucose PET/CT. (2021) (13)
Implications of occult metastatic cells for systemic cancer treatment in patients with breast or gastrointestinal cancer. (2001) (13)
Facilitating Early Integration of Palliative Care into Breast Cancer Therapy. Promoting Disease-Specific Guidelines (2011) (12)
Physician-Based Active Cost Management of Oncological Therapies Reducing Pharmaceutical Costs by 83.4% in Two Years without Leaving Standard of Care (2005) (12)
Abstract P5-15-03: nab-paclitaxel + carboplatin or gemcitabine vs gemcitabine/carboplatin as first-line treatment for patients with triple-negative metastatic breast cancer: Results from the randomized phase 2 portion of the tnAcity trial (2017) (12)
Minimal residual disease in breast cancer and gynecological malignancies: phenotype and clinical relevance. (2003) (12)
Trends in use and outcome of postoperative radiotherapy following mastectomy: A population-based study. (2017) (12)
Zurich Consensus: Statement of German Experts on St. Gallen Conference 2011 on Primary Breast Cancer (Zurich 2011) (2011) (12)
Genomic Profiling in Luminal Breast Cancer (2013) (12)
Recognition and handling of discordant negative human epidermal growth factor receptor 2 classification by Oncotype DX in patients with breast cancer. (2012) (12)
Evaluation of Therapy Management and Patient Compliance in Postmenopausal Patients with Hormone Receptor-positive Breast Cancer Receiving Letrozole Treatment: The EvaluateTM Study. (2014) (12)
The 41-gene classifier TRAR predicts response of HER2 positive breast cancer patients in the NeoALTTO study. (2018) (12)
Interim results of a prospective, open-label, multicentre phase II trial of the efficacy and safety of vinorelbine (N) and trastuzumab (H) in patients with HER2-positive metastatic breast cancer (MBC). (2004) (12)
Neoadjuvant and adjuvant treatment of patients with HER2-positive early breast cancer (2021) (12)
Importance of RIP140 and LCoR Sub-Cellular Localization for Their Association With Breast Cancer Aggressiveness and Patient Survival1 (2018) (12)
Randomised phase III trial of FEC120 vs EC-docetaxel in patients with high-risk node-positive primary breast cancer: final survival analysis of the ADEBAR study (2016) (12)
Cytoplasmic PPARγ is a marker of poor prognosis in patients with Cox-1 negative primary breast cancers (2020) (12)
Comparison of 12 weeks neoadjuvant Nab-Paclitaxel combined with Carboplatinum vs. Gemcitabine in triple negative breast cancer: WSG-ADAPT TN randomized phase II trial (2016) (11)
Association of T-Cell Receptor Repertoire Use With Response to Combined Trastuzumab-Lapatinib Treatment of HER2-Positive Breast Cancer: Secondary Analysis of the NeoALTTO Randomized Clinical Trial (2018) (11)
Clinical Relevance of T1-S, an Oncogene-Inducible, Secreted Glycoprotein of the Immunoglobulin Superfamily, in Node-Negative Breast Cancer (2001) (11)
ABC4 Consensus: Assessment by a German Group of Experts (2018) (11)
Association of TILs with clinical parameters, Recurrence Score® results, and prognosis in patients with early HER2-negative breast cancer (BC)—a translational analysis of the prospective WSG PlanB trial (2020) (11)
eHealth in Modern Patient-Caregiver Communication: High Rate of Acceptance Among Physicians for Additional Support of Breast Cancer Patients During Long-Term Therapy (2016) (11)
Integrating Palliative Medicine into Comprehensive Breast Cancer Therapy – a Pilot Project (2011) (11)
Participation in the SUCCESS-A Trial Improves Intensity and Quality of Care for Patients with Primary Breast Cancer. (2013) (11)
The safety and efficacy of palbociclib in the treatment of metastatic breast cancer (2017) (11)
Abstract P5-19-01: Randomized Phase III trial of afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one prior trastuzumab treatment: LUX-Breast 1 (2015) (11)
Model system for isolation of competent ovarian-carcinoma cells from fresh tumor-tissue by a magnetic separation technique (macs). (1995) (11)
Disseminated tumour cells from the bone marrow of early breast cancer patients: Results from an international pooled analysis. (2021) (11)
AGO Recommendations for the Surgical Therapy of the Axilla After Neoadjuvant Chemotherapy: 2021 Update (2021) (11)
Sorafenib in the Treatment of Early Breast Cancer: Results of the Neoadjuvant Phase II Study - SOFIA* (2014) (11)
Trastuzumab Emtansine Plus Pertuzumab Versus Taxane Plus Trastuzumab Plus Pertuzumab After Anthracycline for High-Risk Human Epidermal Growth Factor Receptor 2–Positive Early Breast Cancer: The Phase III KAITLIN Study (2021) (11)
COVID-19 vaccination in patients with breast cancer and gynecological malignancies: A German perspective (2021) (11)
Disease processes may be reflected by correlations among tissue kallikrein proteases but not with proteolytic factors uPA and PAI-1 in primary ovarian carcinoma. (2006) (11)
Impact of guideline-based use of uPA/PAI-1 on patient outcome in intermediate-risk early breast cancer (2015) (11)
Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials (2020) (10)
Geriatric assessment and biomarkers in patients with metastatic breast cancer receiving first-line mono-chemotherapy: Results from the randomized phase III PELICAN trial. (2017) (10)
Abstract P4-22-03: Palbociclib in combination with endocrine therapy in treatment-naive and previously treated elderly women with HR+, HER2– advanced breast cancer: a pooled analysis from randomized phase 2 and 3 studies (2017) (10)
Integrating collection of biospecimens in clinical trials: the approach of the European organization for research and treatment of cancer. (2011) (10)
[Tumor-associated prognostic factors of the plasminogen activator family: determination and clinical value of u-PA, t-PA, PAI-1, and PAI-2]. (2005) (10)
Prognostic Factors for Overall Survival in Patients with Hormone Receptor‐Positive Advanced Breast Cancer: Analyses From PALOMA‐3 (2021) (10)
Modern Risk Assessment for Individualizing Treatment Concepts in Early-stage Breast Cancer. (2013) (10)
Postoperative Sense of Well-Being and Quality of Life in Breast Cancer Patients Do not Depend on Type of Primary Surgery (2008) (10)
Phase III, randomized, double-blind, placebo-controlled study of ribociclib (LEE011) in combination with either tamoxifen and goserelin or a non-steroidal aromatase inhibitor (NSAI) and goserelin for the treatment of premenopausal women with HR+, HER2- advanced breast cancer (aBC): MONALEESA-7. (2015) (10)
Abstract P4-11-01: Prognostic impact of discordance between different risk assessment tools in early breast cancer (recurrence score, central grade, Ki67): Early outcome analysis from the prospective phase III WSG-PlanB trial (2015) (10)
Abstract S6-07: Comparison of 12 weeks neoadjuvant Nab-paclitaxel combined with carboplatinum vs. gemcitabine in triple- negative breast cancer: WSG-ADAPT TN randomized phase II trial (2016) (10)
Multicenter study validates PITX2 DNA methylation for risk prediction in tamoxifen-treated, node-negative breast cancer using paraffin-embedded tumor tissue (2005) (10)
CD87-positive tumor cells in bone marrow aspirates identified by confocal laser scanning fluorescence microscopy. (1999) (10)
Pretreatment quality of life, performance status and their relation to treatment discontinuation and treatment changes in high-risk breast cancer patients receiving chemotherapy: results from the prospective randomized ADEBAR trial (2016) (10)
COVID-19 Sequelae and the Host Proinflammatory Response: An Analysis From the OnCovid Registry (2022) (10)
Abstract GS5-06: No survival benefit of chemotherapy escalation in patients with pCR and “high-immune” triple-negative early breast cancer in the neoadjuvant WSG-ADAPT-TN trial (2019) (10)
A new look at node-negative breast cancer. (2010) (10)
Tumor angiogenesis as prognostic and predictive marker for chemotherapy dose-intensification efficacy in high-risk breast cancer patients within the WSG AM-01 trial (2011) (10)
Genomic Profiling of Premenopausal HR+ and HER2– Metastatic Breast Cancer by Circulating Tumor DNA and Association of Genetic Alterations With Therapeutic Response to Endocrine Therapy and Ribociclib (2021) (10)
Final analysis of WSG-ADAPT HER2+/HR- trial: Efficacy, safety, and predictive markers for 12-weeks of neoadjuvant dual blockade with trastuzumab + pertuzumab {+/-} weekly paclitaxel in HER2+/HR- early breast cancer (EBC). (2016) (10)
Efficacy of 12 weeks neoadjuvant nab-paclitaxel combined with carboplatinum vs. gemcitabine in triple-negative breast cancer: WSG-ADAPT TN randomized phase II trial. (2015) (9)
Treatment of Early Breast Cancer Patients: Evidence, Controversies, Consensus: Focusing on Systemic Therapy – German Experts’ Opinions for the 16th International St. Gallen Consensus Conference (Vienna 2019) (2019) (9)
Prospects for clinical decision support in breast cancer based on neural network analysis of clinical survival data (2000) (9)
AGO Recommendations for Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer. Update 2011 (2011) (9)
Advanced statistical methods for the definition of new staging models. (2003) (9)
Breast Cancer Is Our Global Responsibility (2015) (9)
Impact of palbociclib plus letrozole on health related quality of life (HRQOL) compared with letrozole alone in treatment naïve postmenopausal patients with ER+ HER2- metastatic breast cancer (MBC): results from PALOMA-2 (2016) (9)
NGS-guided precision oncology in metastatic breast and gynecological cancer: first experiences at the CCC Munich LMU (2020) (9)
Abstract GS4-03: Neoadjuvant nab-paclitaxel weekly versus dose-dense paclitaxel followed by dose-dense EC in high risk HR+/HER2- early BC by: Results from the neoadjuvant part of ADAPT HR+/HER2- trial (2021) (9)
TP53 mutations are associated with primary endocrine resistance in luminal early breast cancer (2021) (9)
Prospective Multicenter Randomized Phase III Study of Weekly versus Standard Docetaxel plus Doxorubicin (D4) for First-Line Treatment of Metastatic Breast Cancer (2011) (9)
De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR-): survival outcomes from a multicentre, open-label, randomised, phase 2 trial. (2022) (9)
A randomized double-blind phase II study of the combination of oral WX-671 plus capecitabine versus capecitabine monotherapy in first-line HER2-negative metastatic breast cancer (MBC). (2013) (9)
Safety Profile of Biosimilar Filgrastim (Zarzio/Zarxio): A Combined Analysis of Phase III Studies. (2018) (9)
Overall survival (OS) with palbociclib plus fulvestrant in women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): Analyses from PALOMA-3. (2018) (9)
Short term quality of life with epirubicin-fluorouracil-cyclophosphamid (FEC) and sequential epirubicin/cyclophosphamid-docetaxel (EC-DOC) chemotherapy in patients with primary breast cancer - Results from the prospective multi-center randomized ADEBAR trial. (2016) (9)
Second International Consensus Conference on Advanced Breast Cancer (ABC2), Lisbon, 11/09/2013: The German Perspective (2014) (9)
Palbociclib (PAL) in combination with fulvestrant (F) in pre-/peri-menopausal (PreM) women with metastatic breast cancer (MBC) and prior progression on endocrine therapy – results from Paloma-3. (2016) (9)
Association between breast cancer risk factors and molecular type in postmenopausal patients with hormone receptor-positive early breast cancer (2019) (9)
Recent advances in technologies for the detection of occult metastatic cells in bone marrow of breast cancer patients (2001) (9)
ADAPT: Adjuvant dynamic marker-adjusted personalized therapy trial optimizing risk assessment and therapy response prediction in early breast cancer. (2013) (9)
KEYLYNK-009: A phase II/III, open-label, randomized study of pembrolizumab (pembro) plus olaparib vs pembro plus chemotherapy after induction with first-line pembro plus chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC). (2020) (9)
Disease processes may be reflected by correlations among tissue kallikrein proteases but not with proteolytic factors uPA and PAI-1 in primary ovarian carcinoma (2006) (9)
Cytoplasmic and Nuclear Forms of Thyroid Hormone Receptor β1 Are Inversely Associated with Survival in Primary Breast Cancer (2020) (8)
Abstract P6-09-10: Results of multigene assay (MammaPrint®) and molecular subtyping (BluePrint®) substantially impact treatment decision making in early breast cancer: Final analysis of the WSG PRIME decision impact study (2017) (8)
ASCO-recommended prognostic factors uPA/PAI-1 in node-negative (N0) breast cancer patients (pts) compared to clinicopathological risk assessment within the NNBC 3-Europe trial. (2009) (8)
Inter‐observer agreement for the histological diagnosis of invasive lobular breast carcinoma (2021) (8)
SANDPIPER: Phase III study of the PI3-kinase (PI3K) inhibitor taselisib (GDC-0032) plus fulvestrant in patients (pts) with oestrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer (BC) enriched for pts with PIK3CA-mutant tumours (2016) (8)
European cost-effectiveness study of uPA/PAI-1 biomarkers to guide adjuvant chemotherapy decisions in breast cancer. (2016) (8)
Influence of patient and tumor characteristics on therapy persistence with letrozole in postmenopausal women with advanced breast cancer: results of the prospective observational EvAluate-TM study (2019) (8)
A phase III trial of nivolumab with neoadjuvant chemotherapy and adjuvant endocrine therapy in ER+/HER2- primary breast cancer: CheckMate 7FL. (2020) (8)
Prognostic impact of 21 Gene Recurrence Score, IHC4, and central grade in high-risk HR+/HER2- early breast cancer (EBC): 5-year results of the prospective Phase III WSG PlanB trial. (2016) (8)
Critical Appraisal of Primary Systemic Endocrine Therapy in Receptor-Positive Postmenopausal Breast Cancer: An Update (2006) (8)
Impact of tumor biology, particularly triple-negative status, on response to pre-operative sequential, dose-dense epirubicin, cyclophosphamide followed by docetaxel in breast cancer. (2010) (8)
Update 2010 of the German AGO Recommendations for the Diagnosis and Treatment of Early and Metastatic Breast Cancer – Chapter B: Prevention, Early Detection, Lifestyle, Premalignant Lesions, DCIS, Recurrent and Metastatic Breast Cancer (2010) (8)
Pooled analysis (n=8,377) evaluates predictive impact of uPA and PAI-1 for response to adjuvant therapy in breast cancer. (2004) (8)
eHealth solutions for therapy management in oncology (2017) (8)
AGO Recommendations for Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2013 (2013) (8)
Impact of tumor biological factors on response to pre-operative epirubicin and paclitaxel chemotherapy in primary breast cancer. (2007) (8)
Sequential Treatment with Epirubicin/Cyclophosphamide, Followed by Docetaxel Is Equieffective, but Less Toxic Than FEC120 in the Adjuvant Treatment of Breast Cancer Patients with Extensive Lymph Node Involvement: The German ADEBAR Phase III Study. (2009) (8)
ABC3 Consensus Commented from the Perspective of the German Guidelines (2016) (8)
A Comparison of Proposed Biosimilar and Originator Filgrastim for the Prevention of Neutropenia in Patients with Breast Cancer Receiving Myelosuppressive Adjuvant or Neoadjuvant Chemotherapy: Phase III, Randomized, Double-Blind Trial (The PIONEER study) (2014) (8)
Phase II, two-arm, double-blind, multicenter, randomized study of the combination of oral WX-671 plus capecitabine versus capecitabine in first-line HER2-negative metastatic breast cancer (MBC). (2010) (8)
Abstract GS4-04: Endocrine therapy alone in patients with intermediate or high-risk luminal early breast cancer (0-3 lymph nodes), Recurrence Score <26 and Ki67 response after preoperative endocrine therapy: Primary outcome results from the WSG-ADAPT HR+/HER2- trial (2021) (8)
Patient's Anastrozole Compliance to Therapy (PACT) Program: Baseline Data and Patient Characteristics from a Population-Based, Randomized Study Evaluating Compliance to Aromatase Inhibitor Therapy in Postmenopausal Women with Hormone-Sensitive Early Breast Cancer (2013) (8)
Comparison of outcome prediction in node-negative breast cancer based on biomarkers uPA/PAI-1 or Adjuvant Online using the 10-year follow-up of the randomized multicenter Chemo N0 trial. (2006) (8)
Anthracyclines Strike Back: Rediscovering Non-Pegylated Liposomal Doxorubicin in Current Therapeutic Scenarios of Breast Cancer (2021) (8)
Alpha-smooth Muscle Actin Expression in the Stroma Predicts Resistance to Trastuzumab in Patients with Early-stage HER2-positive Breast Cancer (2021) (7)
No Clinical Evidence for Increase in Tumour Malignant Potential in Patients (Pts) with Metastatic Breast Cancer (mBC) Treated with Bevacizumab (BV) and Docetaxel (D) in the Phase III AVADO Study. (2009) (7)
Fluorescence Analysis of Vitamin D Receptor Status of Circulating Tumor Cells (CTCS) in Breast Cancer: From Cell Models to Metastatic Patients (2016) (7)
Prognostic impact of residual disease in simultaneous additional excision specimens after one-step breast conserving therapy with negative final margin status in primary breast cancer. (2018) (7)
Significance of prospective multicenter decision impact WSG-BCIST Study in postmenopausal ER+ HER2- N0 early breast cancer (EBC) for molecular testing for intrinsic subtype definition. (2015) (7)
291PPALOMA-2: Neutropenia (NP) patterns in patients (Pts) with estrogen receptor−positive (ER+)/human epidermal growth factor receptor 2−negative (HER2–) first-line advanced breast cancer (ABC) receiving palbociclib + letrozole (P+L) (2017) (7)
Gene signatures in patients with early breast cancer and relapse despite pathologic complete response (2022) (7)
Immune Markers and Tumor-Related Processes Predict Neoadjuvant Therapy Response in the WSG-ADAPT HER2-Positive/Hormone Receptor-Positive Trial in Early Breast Cancer (2021) (7)
De-escalated chemotherapy versus endocrine therapy plus pertuzumab+ trastuzumab for HR+/HER2+ early breast cancer (BC): First efficacy results from the neoadjuvant WSG-TP-II study. (2020) (7)
The impact of anthracyclines in intermediate and high-risk HER2-negative early breast cancer—a pooled analysis of the randomised clinical trials PlanB and SUCCESS C (2022) (7)
Safety analysis of proposed pegfilgrastim biosimilar in Phase I and Phase III studies. (2019) (7)
KEYNOTE-756: Randomized, double-blind, phase 3 study of pembrolizumab vs placebo combined with neoadjuvant chemotherapy and adjuvant endocrine therapy for high-risk, early-stage estrogen receptor–positive, human epidermal growth factor receptor 2–negative (ER+/HER2−) breast cancer. (2019) (7)
EVA-Scalp: Evaluation of Patient Satisfaction with a Scalp Cooling Device to Prevent Chemotherapy-Induced Alopecia in Breast Cancer Patients (2019) (7)
Abstract GS1-01: KEYNOTE-522 study of neoadjuvant pembrolizumab + chemotherapy vs placebo + chemotherapy, followed by adjuvant pembrolizumab vs placebo for early-stage TNBC: Event-free survival sensitivity and subgroup analyses (2022) (7)
[u-Plasminogen activator (urinary plasminogen activator, urokinase) (uPA) and its PA-1 type 1 inhibitor are not only prognostically but also predictively significant and support clinical decisions on therapy in primary carcinoma of the breast]. (2003) (7)
uPA and PAI-1 as biomarkers in breast cancer: validated for clinical use in level-of-evidence-1 studies (2014) (7)
Prognostic Relevance of RIP140 and ERβ Expression in Unifocal Versus Multifocal Breast Cancers: A Preliminary Report (2019) (7)
Implementation of Precision Oncology for Patients with Metastatic Breast Cancer in an Interdisciplinary MTB Setting (2021) (6)
Phase III study evaluating the role of docetaxel in the adjuvant setting of breast cancer patients with ≥ 4 involved lymph nodes: ADEBAR-Study (2005) (6)
Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial. (2018) (6)
German Adjuvant Intergroup Node Positive (GAIN) study: A phase III trial to compare IDD-ETC versus EC-TX in patients with node-positive primary breast cancer—Final efficacy analysis. (2014) (6)
Factors Influencing Decision-Making for or against Adjuvant and Neoadjuvant Chemotherapy in Postmenopausal Hormone Receptor-Positive Breast Cancer Patients in the EvAluate-TM Study (2016) (6)
G-CSF in the Prevention of Febrile Neutropenia in Chemotherapy in Breast Cancer Patients (2006) (6)
Tumor-associated overexpression of the soluble T1-S receptor in lymph node-negative breast cancer. (2000) (6)
ADAPTcycle: Adjuvant dynamic marker-adjusted personalized therapy (ADAPT) comparing endocrine therapy plus ribociclib versus chemotherapy in intermediate-risk HR+/HER2- early breast cancer (EBC). (2019) (6)
LBA76_PR Expected medium and long term impact of the COVID-19 outbreak in oncology (2020) (6)
The Oncological Emergency Case: Paraneoplastic Hypoglycemia in Metastatic Breast Cancer - Case Report and Brief Review of the Literature (2013) (6)
Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials (2020) (6)
Abstract OT3-2-04: ADAPT - Adjuvant Dynamic marker-Adjusted Personalized Therapy trial optimizing risk assessment and therapy response prediction in early breast cancer (2015) (6)
Update Breast Cancer 2020 Part 5 – Moving Therapies From Advanced to Early Breast Cancer Patients (2021) (6)
Associations Between Hospital and Patient Characteristics and Breast Cancer Patients’ Satisfaction With Nursing Staff (2012) (6)
Ovarian Function Suppression: A Deeper Consideration of the Role in Early Breast Cancer and its Potential Impact on Patient Outcomes: A Consensus Statement from an International Expert Panel (2022) (6)
Proposed biosimilar pegfilgrastim (LA-EP2006) compared with reference pegfilgrastim in Asian patients with breast cancer: an exploratory comparison from two Phase III trials. (2017) (6)
Infrared molecular fingerprinting of blood-based liquid biopsies for the detection of cancer (2021) (6)
Updated overall survival (OS) and quality of life (QoL) in premenopausal patients (pts) with advanced breast cancer (ABC) who received ribociclib (RIB) or placebo (PBO) plus goserelin and a nonsteroidal aromatase inhibitor (NSAI) in the MONALEESA-7 (ML-7) trial (2019) (6)
Abstract GS1-04: Copy number aberration analysis to predict response to neoadjuvant anti-HER2 therapy: Results from the NeoALTTO phase III trial (2018) (5)
Abstract OT2-07-03: IMpassion031: A phase III study comparing neoadjuvant atezolizumab vs placebo in combination with nab-paclitaxel–based chemotherapy in early triple-negative breast cancer (TNBC) (2018) (5)
ABC1 Consensus Conference – a German Perspective (2012) (5)
STAT3 activation in HER2‐positive breast cancers: Analysis of data from a large prospective trial (2020) (5)
Evaluation of an interdisciplinary palliative care inhouse training for professionals in gynecological oncology (2018) (5)
Neoadjuvant eribulin in HER2-negative early-stage breast cancer (SOLTI-1007-NeoEribulin): a multicenter, two-cohort, non-randomized phase II trial (2021) (5)
ABC2 Consensus Conference on Advanced Breast Cancer: Brief Summary of the Consensus Panel on Saturday November 9, 2013 (2013) (5)
Emerging strategies in neoadjuvant treatment of patients with HER2-positive early breast cancer. (2019) (5)
Histology-agnostic approvals for antibody-drug conjugates in solid tumours: is the time ripe? (2022) (5)
Clinical Relevance of Detection of Tumor Cells in the Bone Marrow of Primary Breast Cancer Patients: A Review (1997) (5)
Optimal Sequencing of Anti-HER2 Therapy Throughout the Continuum of HER2-Positive Breast Cancer: Evidence and Clinical Considerations (2013) (5)
Determination of ASCO recommended prognostic factors uPA and PAI-1 in daily clinical routine and the node-negative NNBC 3-Europe trial (2009) (5)
4th International Consensus Conference on Advanced Breast Cancer (ABC4), Lisbon, November 4, 2017 * (2018) (5)
Molecular risk estimation and adjuvant chemotherapy in node-negative breast cancer patients-A status report of the prospective clinical trial NNBC 3-Europe. (2006) (5)
Treatment of Patients with Early Breast Cancer: Evidence, Controversies, Consensus (2021) (5)
Integrated Molecular and Immune Phenotype of HER2-Positive Breast Cancer and Response to Neoadjuvant Therapy: A NeoALTTO Exploratory Analysis (2021) (5)
Interim results of Intergroup EC-Doc Trial: A randomized multicenter phase III trial comparing adjuvant CEF/CMF to EC- docetaxel in patients with 1–3 positive lymph nodes (2008) (5)
Zurich Consensus: German Expert Opinion on the St. Gallen Votes on 15 March 2009 (11th International Conference at St. Gallen: Primary Therapy of Early Breast Cancer) (2009) (5)
Neoadjuvant trastuzumab (H), pertuzumab (P), and chemotherapy versus trastuzumab emtansine (T-DM1) and P in human epidermal growth factor receptor 2 (HER2)-positive breast cancer (BC): Final outcome results from the phase III KRISTINE study. (2019) (5)
Abstract GS4-01: Results from CONTESSA: A phase 3 study of tesetaxel plus a reduced dose of capecitabine versus capecitabine alone in patients with HER2-, hormone receptor + (HR+) metastatic breast cancer (MBC) who have previously received a taxane (2021) (5)
Optimal Strategies for Successful Initiation of Neratinib in Patients with HER2-Positive Breast Cancer. (2021) (5)
Improvement of Safety Profile of Docetaxel by Weekly Administration in Patients with Metastatic Breast Cancer (2007) (5)
[Breast cancer. Individualized therapy concepts]. (2013) (5)
[Evidence-based recommendations on treating locoregional and distant metastases of carcinomas of the breast]. (2002) (5)
Abstract P5-19-12: Subgroup analysis on efficacy in the routine treatment - Results of the 2nd interim analysis of BRAWO, the non-interventional trial "Breast Cancer Treatment with Everolimus and Exemestane for HR+ Women" (2015) (5)
Abstract P6-14-05: Final Overall Survival Analysis of the TBP Phase III Study (GBG 26/BIG 3-05): Capecitabine vs. Capecitabine + Trastuzumab in Patients with HER2-Positive Metastatic Breast Cancer Progressing during Trastuzumab Treatment (2010) (5)
Abstract S2-2: Multivariate Analysis of Obesity and Disease Free Survival in Patients with Nodal Positive Primary Breast Cancer — The ADEBAR Trial (2010) (5)
Truly personalized therapy — an end to the era of one size fits all (2019) (5)
Multi-center validation of the 76-gene prognostic signature in lymph node negative (LNN) primary breast cancer (2005) (5)
Abstract OT1-1-16: LUX-Breast 1: Randomized, Phase III trial of afatinib (BIBW 2992) and vinorelbine vs. trastuzumab and vinorelbine in patients with HER2-overexpressing metastatic breast cancer (MBC) failing one prior trastuzumab treatment* (2012) (5)
Clinical validity and clinical utility of Ki67 in early breast cancer (2022) (5)
Anthracyclines for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Are We Ready to Let Them Go? (2021) (5)
Benefits of early and prolonged fulvestrant treatment in 848 postmenopausal advanced breast cancer patients (2010) (5)
Changes in gynecologic and breast cancer diagnoses during the first wave of the COVID-19 pandemic: analysis from a tertiary academic gyneco-oncological center in Germany (2021) (5)
Phenotype Discordance between Primary Tumor and Metastasis Impacts Metastasis Site and Outcome: Results of WSG-DETECT-PriMet (2020) (5)
Local Resection of Primary Tumor in Upfront Stage IV Breast Cancer (2016) (5)
Treatment strategies that effectively reduce early recurrence risk in postmenopausal women with endocrine-sensitive breast cancer: AIs upfront vs. switching (2007) (4)
Quality-of-life methodology in hormone receptor–positive advanced breast cancer: current tools and perspectives for the future (2021) (4)
Corrections to "Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expression". (2017) (4)
Handbook of HER2-Targeted Agents in Breast Cancer. (2014) (4)
Abstract OT2-11-09: Lidera breast cancer: A phase III adjuvant study of giredestrant (GDC-9545) vs physician’s choice of endocrine therapy (ET) in patients (pts) with estrogen receptor-positive, HER2-negative early breast cancer (ER+/HER2- EBC) (2022) (4)
Erratum to: ‘Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial (2016) (4)
DNA methylation profile predicts risk of recurrence in tamoxifen-treated, node-negative breast cancer patients. (2004) (4)
BRCA1-like copy number profiles to predict benefit of high-dose alkylating chemotherapy in high-risk breast cancer (BC): Results from randomized WSG AM-01 trial. (2014) (4)
Susceptibility to hormone-mediated cancer is reflected by different tick rates of the epithelial and general epigenetic clock (2022) (4)
Phase II study of metronomic treatment with daily oral vinorelbine as first-line chemotherapy in patients with advanced/metastatic HR+/HER2− breast cancer resistant to endocrine therapy: VinoMetro—AGO-B-046 (2021) (4)
Abstract P1-12-03: Short term quality of life with epirubicin-fluorouracil-cyclophosphamid (FEC) and sequential epirubicin/cyclophosphamid-docetaxel (EC-DOC) chemotherapy in patients with primary breast cancer – Results from the prospective multi-center randomized Adebar trial (2016) (4)
Abstract OT3-2-10: Phase 3, multicenter, randomized, double-blind, placebo-controlled trial of fulvestrant with or without PD-0332991 (palbociclib) ± goserelin in women with hormone receptor-positive, HER2-negative metastatic breast cancer (MBC) whose disease progressed after prior endocrine therapy (2013) (4)
The use of breast ultrasound for prediction of pathologic complete response in different subtypes of early breast cancer within the WSG-ADAPT subtrials (2021) (4)
Neoadjuvant treatment of HER2-positive breast cancer: should therapy differ based on hormone receptor status? (2018) (4)
Preexisting musculoskeletal burden and its development under letrozole treatment in early breast cancer patients (2019) (4)
276O Pooled analysis of patient (pt)-reported quality of life (QOL) in the MONALEESA (ML)-2, -3, and -7 trials of ribociclib (RIB) plus endocrine therapy (ET) to treat hormone receptor–positive, HER2-negative (HR+/HER2−) advanced breast cancer (ABC) (2020) (4)
Update Breast Cancer 2022 Part 2 – Advanced Stage Breast Cancer (2022) (4)
In-depth gene expression analysis of premenopausal patients with HR+/HER2− advanced breast cancer (ABC) treated with ribociclib-containing therapy in the Phase III MONALEESA-7 trial. (2019) (4)
First-Line Doublet Chemotherapy for Metastatic Triple-Negative Breast Cancer: Circulating Tumor Cell Analysis of the tnAcity Trial (2019) (4)
Does the Presence of Circulating Tumor Cells in High-Risk Early Breast Cancer Patients Predict the Site of First Metastasis—Results from the Adjuvant SUCCESS A Trial (2022) (4)
Prospective comparison of recurrence score, uPA/PAI-1, central grade and molecular classification in early breast cancer: Interim results from the WSG-Plan B trial. (2011) (4)
tnAcity: A phase II/III trial of weekly nab-paclitaxel (nab-P) plus gemcitabine (gem) or carboplatin (carbo) versus gem/carbo as first-line treatment for metastatic triple-negative breast cancer (mTNBC). (2014) (4)
114PMolecular imaging with 18F-fluoroestradiol (18F-FES) to assess intra-patient heterogeneity in metastatic breast cancer (MBC): A European TRANSCAN program (2017) (4)
1O KEYNOTE-522 Asian subgroup: Phase III study of neoadjuvant pembrolizumab (pembro) vs placebo (pbo) + chemotherapy (chemo) followed by adjuvant pembro vs pbo for early triple-negative breast cancer (TNBC) (2020) (4)
PD07-05: Local Recurrence Risk in 6377 Patients with Early Breast Cancer Receiving Neoadjuvant Anthracycline-Taxane +/− Trastuzumab Containing Chemotherapy. (2011) (4)
Toxicity in elderly breast cancer patients treated by a taxane based chemotherapy as adjuvant or neoadjuvant therapy for primary breast cancer. (2006) (4)
Correlation between work productivity loss and EORTC QLQ-C30 and -BR23 domains from the MONALEESA-7 trial of premenopausal women with HR+/HER2− advanced breast cancer (2022) (4)
Abstract P5-18-06: Trastuzumab emtansine in HER2-positive metastatic breast cancer: pooled safety analysis from seven studies (2012) (4)
Neoadjuvant and adjuvant end-points in health technology assessment in oncology. (2021) (4)
Incorporation of a Comprehensive Geriatric Assessment (CGA) into a randomized phase III trial for metastatic breast cancer: The PELICAN Study. (2009) (4)
The patient experience (2007) (4)
Phase III study evaluating the role of docetaxel in the adjuvant therapy of breast cancer patients with extensive lymph node involvement (4 nodes+) — ADEBAR study (2003) (4)
Assessment of Quality of Life in Postmenopausal Women with Early Breast Cancer Participating in the PACT Trial: The Impact of Additional Patient Information Material Packages and Patient Compliance. (2019) (4)
Endometrial effects of exemestane compared to tamoxifen within the TEAM trial: Results of a prospective randomized study (2007) (4)
Impact of uPA/PAI-1 and disseminated cytokeratin-positive cells in breast cancer (2019) (4)
Pattern of care of adjuvant radiotherapy in male breast cancer patients in clinical practice: an observational study (2018) (4)
Abstract GS1-01: Primary outcome analysis of invasive disease-free survival for monarchE: abemaciclib combined with adjuvant endocrine therapy for high risk early breast cancer (2021) (4)
First Experiences with Alpelisib in Clinical Routine: Case Reports from a German Breast Center (2021) (4)
Multiple Bayesian network meta-analyses to establish therapeutic algorithms for metastatic triple negative breast cancer. (2022) (4)
[Prenatal manifestation of a congenital glioblastoma - Case report]. (2002) (4)
Epigenetic signature predicts failure of endocrine therapy in patients with recurrent breast cancer (2003) (4)
LBA14 De-escalated neoadjuvant T-DM1 with or without endocrine therapy (ET) vs trastuzumab+ET in early HR+/HER2+ breast cancer (BC): ADAPT-TP survival results (2020) (4)
The combination of sorafenib and everolimus in patients with solid tumors: Results of a phase I study. (2011) (4)
Abstract P1-08-42: High HER2 expression correlates with response to trastuzumab and the combination of trastuzumab and lapatinib in the NeoALTTO phase III trial (2013) (4)
Prospective study comparing hospital costs and DRG reimbursement of inpatient treatment of febrile neutropenia during adjuvant anthracycline-based CTX for primary breast cancer. (2009) (4)
Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expression. (2017) (4)
AGO Recommendations for the Surgical Therapy of Breast Cancer: Update 2022 (2022) (4)
1937 Clinical impact of risk classification by central/local grade or luminal-like subtype vs. Oncotype DX®: First prospective survival results from the WSG phase III planB trial (2015) (4)
Copy number aberration analysis to predict response to neoadjuvant anti-HER2 therapy: Results from the NeoALTTO phase III trial (2017) (4)
Randomized, phase II study of two doses of pemetrexed as first-line chemotherapy for locally advanced or metastatic breast cancer (MBC): Clinical results and exploratory pharmacogenomic analysis. (2006) (4)
Breast cancer: Increasing therapy options for HER2-positive early breast cancer (2011) (4)
The EUSOMA recommendations for the management of young women with breast cancer (2012) (4)
BIBW 2992, a Novel Irreversible EGFR/HER1 and HER2 Tyrosine Kinase Inhibitor for the Treatment of Patients with HER2-Negative Metastatic Breast Cancer after Failure of No More Than Two Prior Chemotherapies. (2009) (4)
Five-year results of the prospective Phase III WSG PlanB trial confirm prognostic impact of 21-Gene Recurrence Score in high-risk HR+/HER2-early breast cancer (EBC) patients with 1-3 involved lymph nodes (2017) (3)
Abstract P4-10-05: Predictive value of HER2 expression, early response and tumor infiltrating lymphocytes (TILs) on efficacy of de-escalated pertuzumab+trastuzumab in the neoadjuvant WSG-ADAPT-HER2+/HR- trial (2020) (3)
COVID-19 in breast cancer patients: a subanalysis of the OnCovid registry (2021) (3)
Side-effects of pre-operative epirubicin-paclitaxel therapy in primary breast cancer associated with tumor biology. (2009) (3)
Optimized pro-active management of anemia by Epoetin alpha in pre-operative chemotherapy for primary breast cancer. (2009) (3)
3D breast ultrasound: a significant predictor in breast cancer reduction under pre-operative chemotherapy. (2011) (3)
Digitalization in Medicine: It Is Our Chance and Responsibility Now to Shape the Digital Future of Breast Cancer Management (2019) (3)
Struggling with subtypes: trying to bridge the gap between molecular breast cancer subtypes and clinical management (2011) (3)
Never too late: reducing late breast cancer relapse risk. (2008) (3)
First results from the Patient's Anastrozole Compliance to Therapy (PACT) program evaluating the influence of a standardized information service on compliance in postmenopausal women with early breast cancer (EBC). (2010) (3)
Human kallikrein 5 (hK5): A hovel serum biomarker for ovarian and breast cancer. (2003) (3)
AGO Recommendations for Diagnosis and Treatment of Patients with Early and Metastatic Breast Cancer: Update 2012 (2012) (3)
Congruence and trajectories of device-measured and self-reported physical activity during therapy for early breast cancer (2021) (3)
ABC4 Consensus: Assessment by a Panel of German Experts* (2018) (3)
Abstract P6-18-14: Patient-reported outcomes with ribociclib-based therapy in hormone receptor-positive, HER2-negative advanced breast cancer: results from the phase III MONALEESA-2, -3, and -7 trials (2019) (3)
P5-17-05: 24 Months Follow-Up Results from PACT (Patient's Anastrozole Compliance to Therapy Programme), a Non-Interventional Study Evaluating the Influence of a Standardized Information Service on Compliance in Postmenopausal Women with Early Breast Cancer. (2011) (3)
Abstract P1-13-13: First planned efficacy analysis of the NNBC 3-Europe trial: Addition of docetaxel to anthracycline containing adjuvant chemotherapy in high risk node-negative breast cancer patients. (2012) (3)
Trastuzumab Biosimilars in the Therapy of Breast Cancer – “Real World” Experiences from four Bavarian University Breast Centres (2020) (3)
Biomarkers for breast cancer: Towards the proposition of clinically relevant tools (2008) (3)
Reply to 'The St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017: the point of view of an International Panel of Experts in Radiation Oncology' by Kirova et al. (2017) (3)
Sequential treatment with epirubicin/cyclophosphamide, followed by docetaxel versus FEC120 in the adjuvant treatment of node-positive breast cancer patients: Final survival analysis of the German ADEBAR phase III study. (2012) (3)
Molecular Prognostic Factors for Distant Metastases in Premenopausal Patients with HR+/HER2− Early Breast Cancer (2021) (3)
Abstract P1-09-09: Efficacy and gene expression results from SOLTI1007 NEOERIBULIN phase II clinical trial in HER2-negative early breast cancer (2017) (3)
Interim safety analysis of a randomized phase III study evaluating pegylated liposomal doxorubicin (PLD) versus capecitabine as first line chemotherapy for metastatic breast cancer (MBC) – The PELICAN study (2008) (3)
Correction to: Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial (2019) (3)
Impact of palbociclib plus fulvestrant on patient reported general health status compared with fulvestrant alone in HR + , HER2- metastatic breast cancer (2016) (3)
LBA11Prognostic impact of recurrence score (RS), grade/Ki67 central pathological review, and acycline (A)-free vs. A-containing chemotherapy (CT) on distant and locoregional disease-free survival (DDFS/LRFS) in high clinical risk HER2- early breast cancer (EBC): WSG PlanB trial results (2017) (3)
Abstract GS3-02: Patient-reported outcomes (PROs) from the Ph 3 IMpassion031 trial of neoadjuvant (NA) atezolizumab + chemo in early triple-negative breast cancer (eTNBC) (2021) (3)
Abstract OT3-05-05: MonarchE: A randomized, open-label, phase 3 study of abemaciclib combined with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone in patients with high risk, node positive, early stage, HR+, HER2- breast cancer (2018) (3)
Identification, validation and clinical implementation of cancer biomarkers: Translational strategies of the EORTC PathoBiology Group (2012) (3)
Prospective comparison of recurrence score and independent central pathology assessment of prognostic tools in early breast cancer (BC): Focus on HER2, ER, PR, Ki-67 results from the phase III WSG-Plan B trial. (2012) (3)
Decision Support in Breast Cancer: Recent Advances in Prognostic and Predictive Techniques (2000) (3)
Complementary and alternative medicine and musculoskeletal pain in the first year of adjuvant aromatase inhibitor treatment in early breast cancer patients (2020) (3)
Comparison of Actual Hospital Costs versus DRG Revenues for In-Patient Treatment of Febrile Neutropenia during Adjuvant Anthracycline plus/minus Taxane-Based Chemotherapy for Primary Breast Cancer (2011) (3)
Cytoplasmic LXR expression is an independent marker of poor prognosis for patients with early stage primary breast cancer (2021) (3)
Impact of 12 weeks nab-paclitaxel + carboplatin or gemcitabine followed by anthracycline administration according to pCR in triple-negative early breast cancer: Survival results of WSG-ADAPT-TN phase II trial. (2018) (3)
Oncotype DX and proliferation response to short-term preoperative endocrine therapy for chemotherapy decision in early breast cancer: Biomarker data from the prospective multicenter phase II/III WSG-ADAPT trial. (2014) (3)
Abstract P5-20-01: A randomized double-blind phase II study of the combination of oral WX-671 plus capecitabine vs. capecitabine monotherapy in first-line HER2− negative metastatic breast cancer (MBC). (2012) (3)
Abstract P2-10-08: Prospective comparison of Recurrence Score and different definitions of luminal subtypes by central pathology assessment of single markers in early breast cancer: results from the phase III WSG-planB Trial (2012) (3)
Phase III study of sequential treatment with epirubicin/cyclophosphamide followed by docetaxel compared to FEC120 in the adjuvant treatment of breast cancer patients: The German ADEBAR study. (2010) (3)
From genomic data analysis to drug development: a new generation of trials using molecular marker assessment in breast cancer (2014) (3)
Evaluation of Reproductive Concerns and Biographical Impact of Breast Cancer in Young Patients (2018) (3)
[Breast cancer: tumor biology-based concepts for surgical and drug treatment]. (2013) (3)
Pandemic Phase-Adjusted Analysis of COVID-19 Outcomes Reveals Reduced Intrinsic Vulnerability and Substantial Vaccine Protection From Severe Acute Respiratory Syndrome Coronavirus 2 in Patients With Breast Cancer. (2023) (3)
American Society of Clinical Oncology highlights 2013: breast cancer and gynecological malignancies. (2013) (3)
Impact of Disease Progression Status on time to Deterioration of Patient Reported Health Related Quality of Life in Forst Line ER+ HER2-VE Advanced/Metastatic Breast Cancer Patients in the PALOMA-2 Study (2017) (3)
Documentation patterns and impact on observed side effects of the CANKADO ehealth application: An exploratory analysis of the PreCycle trial. (2020) (2)
Zurich Consensus: Statement of German Experts on St. Gallen Conference 2011 on Breast Cancer (Zurich 2011) (2011) (2)
Patient's Anastrozole Compliance to Therapy Programme (PACT) influence of the addition of a standardized information and reminder service on compliance in comparison to standard clinical care alone in women with early breast cancer (2008) (2)
ERBB2 mutation is associated with sustained tumor cell proliferation after short-term preoperative endocrine therapy in early lobular breast cancer (2022) (2)
Abstract P1-19-06: Patient-reported outcomes, including work productivity, from the MONALEESA-7 trial of ribociclib plus endocrine therapy in patients with HR+/HER2− advanced breast cancer (2020) (2)
Abstract P2-09-05: Risk Group Selection in Primary Breast Cancer According to ASCO Recommended Biomarkers Onkotype DX and uPA/PAI-1: First Experience from Prospective Multicenter WSG Plan B Trial (2010) (2)
Protroca: A Noninterventional Study on Prophylactic Lipegfilgrastim against Chemotherapy-Induced Neutropenia in Nonselected Breast Cancer Patients (2020) (2)
Influence of sequencing of chemotherapy and radiotherapy regarding adverse effects of the cytostatic treatment: Results of the ADEBAR trial (2007) (2)
Association of molecular subtype, proliferation, and immune genes with efficacy of carboplatin versus gemcitabine addition to taxane-based, anthracycline-free neoadjuvant chemotherapy in early triple-negative breast cancer (TNBC): Results of the randomized WSG ADAPT-TN trial. (2017) (2)
Neratinib as extended adjuvant therapy in patients with copositive early breast cancer: German health technology assessment-driven analyses from the ExteNET study. (2021) (2)
Impact of Granulocyte Colony-Stimulating Factor (G-CSF) and Epoetin (EPO) on Hematologic Toxicities and Quality of Life in Patients During Adjuvant Chemotherapy in Early Breast Cancer: Results From the Multi-Center Randomized ADEBAR Trial. (2020) (2)
[Micrometastases in bone marrow at the time of primary treatment of breast cancer: a new prognostic criterion?]. (1989) (2)
324P What affects the choice of first-line treatment for hormone-receptor-positive, HER2-negative advanced breast cancer? Data from the German research platform OPAL (2020) (2)
Obesity and tumor characteristics in nodal-positive early-stage breast cancer: Results of the German ADEBAR study. (2010) (2)
Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial. (2019) (2)
11th International Conference St. Gallen: Primary Therapy of Early Breast Cancer (2009) (2)
[Tumor biology of primary breast cancer and minimal residual disease]. (2002) (2)
Four Years of Surveying Patients as Part of the Certification/Re-Certification of Breast Centers in North Rhine-Westphalia (2010) (2)
24-month follow-up from the Patient's Anastrozole Compliance to Therapy (PACT) program evaluating the influence of a standardized information service on compliance in postmenopausal women with early breast cancer. (2011) (2)
Risk-adapted adjuvant therapy of luminal early breast cancer in 2020. (2020) (2)
Safety and efficacy of alternating treatment with EP2006, a filgrastim biosimilar, and reference filgrastim for the prevention of severe neutropenia, in patients with breast cancer receiving myelosuppressive chemotherapy. (2017) (2)
EORTC – NCI – ASCO Annual Meeting on “Molecular Markers in Cancer” (2011) (2)
The role of E-Cadherin expression in primary site of breast cancer (2021) (2)
Clinical data for anti-angiogenic agents in previously treated advanced breast cancer (2008) (2)
Pathological complete response rate and survival in patients with BRCA-associated triple-negative breast cancer after 12 weeks of de-escalated neoadjuvant chemotherapy: Translational results of the WSG-ADAPT TN randomized phase II trial (NCT01815242). (2021) (2)
P40 Pooled analysis (n=8,377) validates predictive impactof uPA and PAI-1 for response to adjuvant chemotherapy in breast cancer (2005) (2)
Abstract OT1-03-14: SANDPIPER: Phase III study of the PI3-kinase inhibitor taselisib (GDC-0032) plus fulvestrant in patients with estrogen receptor-positive, HER2-negative locally advanced or metastatic breast cancer enriched for patients withPIK3CA-mutant tumors (2016) (2)
The prognostic and predictive impact of genomic grade index (GGI) versus central grade or molecular class in intermediate-risk breast cancer (BC): Results from the EC-Doc trial. (2013) (2)
A Web- and App-Based Connected Care Solution for COVID-19 In- and Outpatient Care: Qualitative Study and Application Development (Preprint) (2020) (2)
Update on Female Cancer in Africa: The AORTIC Conference 2015, Morocco (2016) (2)
Everolimus (RAD) as treatment in breast cancer patients with bone metastases only: Results of the phase II RADAR study. (2012) (2)
Abstract P4-13-03: Updated safety from a double-blind phase 3 trial (PALOMA-3) of fulvestrant with placebo or with palbociclib in pre- and postmenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer that progressed on prior endocrine therapy (2016) (2)
Abstract P3-11-25: Real-world treatment patterns and clinical outcomes among women with HR+/HER2- advanced or metastatic breast cancer treated in real-world settings in Italy and Germany (2020) (2)
Magnetic resonance imaging and ultrasound for prediction of residual tumor size in early breast cancer within the ADAPT subtrials (2020) (2)
Endocrine Combination Therapy for Prostate and Metastatic Breast Cancer in a Male Patient (2007) (2)
Prognostic impact of recurrence score, endocrine response and clinical-pathological factors in high-risk luminal breast cancer: Results from the WSG-ADAPT HR+/HER2- chemotherapy trial. (2021) (2)
ADAPTlate: A randomized, controlled, open-label, phase III trial on adjuvant dynamic marker—Adjusted personalized therapy comparing abemaciclib combined with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy in (clinical or genomic) high-risk, HR+/HER2- early breast canc (2021) (2)
Copy Number Aberration Analysis to Predict Response to Neoadjuvant Anti-HER2 Therapy: Results from the NeoALTTO Phase III Clinical Trial (2021) (2)
Evolution of the 21-gene Assay Oncotype DX® from an Experimental Assay to an Instrument Assisting in Risk Prediction and Optimisation of Treatment Decision-making in Early Breast Targeted Therapy in Combination with Chemotherapy in Recurrent and/or Metastatic Head and Neck Cancer (2010) (2)
Abstract OT3-3-02: ADAPT - Adjuvant Dynamic marker-Adjusted Personalized Therapy trial optimizing risk assessment and therapy response prediction in early breast cancer (2012) (2)
Abstract P1-09-05: The role of immune and apoptosis markers for prediction of pCR in the WSG-ADAPT HER2+/HR+ phase II trial evaluating 12-weeks of neoadjuvant TDM1 ± endocrine therapy (ET) versus T + ET in HER2-positive hormone-receptor-positive early breast cancer (EBC) (2017) (2)
Long-term prognostic impact of PAI-1 in primary breast cancer confirmed by six-year median follow-up (1997) (2)
[Breast carcinoma. Biological principles, classification and prognostic factors]. (2002) (2)
Contents Vol. 10, 2015 (2015) (2)
212TiPIMpassion031: A phase III study comparing neoadjuvant atezolizumab (atezo) vs placebo in combination with anthracycline/nab-paclitaxel (nab-pac)–based chemotherapy in early triple-negative breast cancer (eTNBC) (2017) (2)
Endometrial safety of cross-over treatment with tamoxifen followed by exemestane (2008) (2)
The safety of palbociclib for the treatment of advanced breast cancer (2018) (2)
FGFR4 Arg388 allele is associated with resistance to adjuvant therapy in primary breast cancer. (2006) (2)
Interim analysis of the multicenter phase II HEDON trial evaluating pathological response to pre-operative docetaxel and docetaxel+trastuzumab (T) in locally advanced breast cancer (BR) stratified by HER2-status. (2009) (2)
Early response by MR imaging and ultrasound as predictor of pathologic complete response to 12‐week neoadjuvant therapy for different early breast cancer subtypes: Combined analysis from the WSG ADAPT subtrials (2021) (2)
AGO Recommendations for the Diagnosis and Therapy of Breast Cancer (2007) (2)
PV-0044 Mastectomy or breast-conserving therapy for early breast cancer: outcome comparison of 7565 cases (2019) (2)
11O Prospective Comparison of Risk Assessment Tools in Early Breast Cancer: Correlation Analysis from the Phase III Wsg-Plan B Trial (2012) (2)
Ribociclib (RIB) plus tamoxifen (TAM) or a non-steroidal aromatase inhibitor (NSAI) in premenopausal women with hormone receptorpositive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): additional results from the MONALEESA-7 trial (2018) (2)
ABC6 Consensus: Assessment by a Group of German Experts (2022) (2)
Breast Cancer in Young Women – a Clinical Challenge to Be Addressed in a Multidisciplinary Setting (2012) (2)
Adjuvant Chemotherapy in Primary Breast Cancer (2006) (2)
The 76-Gene Signature Defines High-Risk Patients That Benefit from Adjuvant Tamoxifen Therapy. (2009) (2)
Evolution of the 21-gene Assay Onco type DX ® from an Experimental Assay to an Instrument Assisting in Risk Prediction and Optimisation of Treatment Decision-making in Early Breast Cancer Breast Cancer (2010) (2)
Moco - Comparison of two different algorithms for motion correction in breast MRI (2008) (2)
Interim safety analysis of the randomized phase III PELICAN trial evaluating pegylated liposomal doxorubicin (PLD) versus capecitabine as first-line therapy for metastatic breast cancer. (2016) (2)
Molecular Mechanisms of Chemoresistance and Potential Means of Overcoming It (2009) (2)
Virtual Science in Senology: Let Us Not Throw out the Baby with the Bathwater (2020) (2)
Abstract OT3-1-11: tnAcity: A phase 2/3 randomized study of weekly nab-paclitaxel in combination with either gemcitabine or carboplatin vs gemcitabine/carboplatin as first-line treatment for triple-negative metastatic breast cancer (2013) (2)
Improved patient management using eHealth tools: potential and pitfalls (2015) (2)
Molecular Subtyping of Invasive Breast Cancer Using a PAM50-Based Multigene Expression Test-Comparison with Molecular-Like Subtyping by Tumor Grade/Immunohistochemistry and Influence on Oncologist’s Decision on Systemic Therapy in a Real-World Setting (2022) (2)
WSG PLAN B trial: Evaluating efficacy of anthracycline-free chemotherapy in primary HER2-negative breast cancer after molecular-based risk assessment according to Oncotype DX and uPA/PAI-1. (2010) (2)
ASTEFANIA: adjuvant ado-trastuzumab emtansine and atezolizumab for high-risk, HER2-positive breast cancer. (2022) (2)
P1-06-03: Predictive Value of HER2, Topoisomerase-II (Topo-II) and Tissue Inhibitor of Metalloproteinases (TIMP-1) for Efficacy of Taxane-Based Chemotherapy in Intermediate Risk Breast Cancer – Results from the EC-Doc Trial. (2011) (2)
Biological risk assessment based on snap frozen tissue samples. Feasibility, qualitiy assuance and study progress of the multicenter trial NNBC 3-Europe (2007) (1)
Primary Tumor in Breast Cancer (BC) and phenotype in positive lymphnodes and later disease recurrence (metastatic breast cancer, MBC): results of the PriMet-trial (WSG / DETECT) (2011) (1)
Chemotherapy Is Not the End of the Road in Young Cancer Patients who Still Want to Become Pregnant (2010) (1)
Current challenges and unmet needs in treating patients with human epidermal growth factor receptor 2-positive advanced breast cancer (2022) (1)
Proposed Biosimilar Pegfilgrastim (LA-EP2006) and Reference Pegfilgrastim for the Prevention of Neutropenia in Patients with Breast Cancer: A Randomized, Double-Blind Trial. Protect 2: Pegfilgrastim Randomized Oncology (supportive care) Trial to Evaluate Comparative Treatment Results (2015) (1)
P73 Phase III study evaluating the role of Docetaxel in theadjuvant therapy of breast cancer patients with extensive lymph node involvement (*4 LK+) — Current State of the ADEBAR Study (2005) (1)
Urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 for improved management in node-negative (N0) breast cancer: Experiences from the ongoing multicenter trial NNBC 3-Europe (2007) (1)
Outcome Prediction in Node-Negative Breast Cancer Based on ASCO-Recommended Biomarkers uPA/PAI-1 Using the Final 10-Year Analysis of the Randomized Multicenter Chemo N0 Trial Compared to Adjuvant Online™. (2009) (1)
Patient-reported outcomes from a randomized trial of neoadjuvant atezolizumab-chemotherapy in early triple-negative breast cancer (2022) (1)
Abstract PS12-01: Pembrolizumab versus chemotherapy for previously treated metastatic triple-negative breast cancer (KEYNOTE-119): Efficacy in patients with lung or liver metastases (2021) (1)
Efficacy and safety results by menopausal status in monarchE: adjuvant abemaciclib combined with endocrine therapy in patients with HR+, HER2−, node-positive, high-risk early breast cancer (2023) (1)
Abstract OT-01-02: Adaptlate -a randomized, controlled, open-label, phase-iii trial on adjuvant dynamic marker - adjusted personalized therapy comparing abemaciclib combined with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy in (clinical or genomic) high risk, hr+/he (2021) (1)
Update Breast Cancer 2022 Part 4 – Advanced-Stage Breast Cancer (2022) (1)
Abstract P2-16-05: Efficacy of response- and toxicity-guided neoadjuvant chemotherapy in elderly early breast cancer patients: Results of WSG ADAPT elderly sub-trial (2020) (1)
C-Met overexpression identifies breast cancer patients with poor clinical outcome independent of Her2/neu. (2003) (1)
Thyroid Hormones and Vitamin D in Patients with Breast Cancer with Mutations in BRCA1 or BRCA2 Genes. (2016) (1)
P246 Risk assessment by St.Gallen 2013 recommendation and Oncotype DX®: results from the WSG PlanB trial (2015) (1)
Abstract P5-04-02: Biopsy of metastases impacts treatment choice and patient outcome in breast cancer – Final results of the WSG/DETECT PRIMET study (2013) (1)
441 Quality Assurance of Biomarker Assays in Clinical Trials (2012) (1)
Final toxicity analysis of the ADEBAR phase III study evaluating the role of docetaxel in the adjuvant therapy of breast cancer patients with extensive lymph node involvement (2007) (1)
Pooled analysis of two randomized, double-blind trials comparing proposed biosimilar LA-EP2006 with reference pegfilgrastim in breast cancer. (2016) (1)
Clinical Experience with Lapatinib in Patients with ErbB2-Overexpressing Metastatic Breast Cancer (2008) (1)
Abstract P4-21-09: Cardiac biomarkers for early detection and prediction of trastuzumab and/or lapatinib-induced cardiotoxicity in patients with HER2 positive early breast cancer (BIG 1-06) (2017) (1)
Fibrinolytics, enzyme inhibitors, and cancer survival (2009) (1)
Association of TILs with clinical parameters, Recurrence Score® results, and prognosis in patients with early HER2-negative breast cancer (BC)—a translational analysis of the prospective WSG PlanB trial (2020) (1)
Distress in hospitalized cancer patients: Associations with personality traits, clinical and psychosocial characteristics (2021) (1)
PG 3.04 Insights in biology of luminal HER2 vs enriched HER2 subtypes: therapeutic implications (2015) (1)
P173 Comparing a novel clinico-pathological risk classification used in the node-negative-breast- cancer-3 (NNBC-3) trial with the establishedSt. Gallen Risk Classification 2005 (2007) (1)
356TiP A phase II/III, open-label, randomized trial of pembrolizumab + olaparib vs. pembrolizumab + chemotherapy after induction with pembrolizumab + chemotherapy in locally recurrent inoperable or metastatic triple-negative breast cancer: KEYLYNK-009 (2020) (1)
KEYNOTE-756: A randomized, double-blind, phase III study of pembrolizumab or placebo with neoadjuvant chemotherapy and adjuvant endocrine therapy for high-risk, early-stage, ER+/HER2−breast cancer (2019) (1)
Weekly nab-paclitaxel (nab-P) plus gemcitabine (gem) or carboplatin (carbo) vs gem/carbo as first-line treatment for metastatic triple-negative breast cancer (mTNBC) in a phase 2/3 trial (tnAcity). (2015) (1)
Physical Activity Associated With Fewer Cancers Response (2016) (1)
Sedatives and Sedation at the End of Life in the Hospital-a Multicenter Retrospective Cohort Study. (2022) (1)
Abstract P6-05-11: Run-in phase of prospective WSG-ADAPT HR+/HER2- trial demonstrates feasibility of early endocrine sensitivity prediction by recurrence score and conventional parameters in clinical routine (2013) (1)
Predictors of efficacy in patients (pts) with hormone receptor–positive/ human epidermal growth factor receptor 2–negative advanced breast cancer (HR+/HER2− ABC): Subgroup analyses of PALOMA-3 (2020) (1)
Whole exome sequencing of pre-treatment biopsies from the neoALTTO trial to identify DNA aberrations associated with response to HER2-targeted therapies (2015) (1)
Abstract OT2-04-03: Nivolumab with neoadjuvant chemotherapy and adjuvant endocrine therapy in ER+/HER2- primary breast cancer: CheckMate 7FL (2020) (1)
Participation in a randomized phase III study (evaluating the role of adjuvant docetaxel in high-risk breast cancer patients) improves treatment strategies and individual patient care in recruiting centers: The ADEBAR-Trial (2005) (1)
[Adjuvant chemotherapy in primary carcinoma of the breast]. (2003) (1)
5080 Safety and tolerability of fulvestrant high-dose (500 mg) in postmenopausal women with hormone receptor positive advanced breast cancer (2009) (1)
LBA5_PR Abemaciclib in high risk early breast cancer (2020) (1)
Interest in integrative medicine among postmenopausal hormone receptor-positive breast cancer patients receiving letrozole treatment in the EvAluate-TM study (2016) (1)
Abstract CT141: Genetic landscape of premenopausal HR+/HER2- advanced breast cancer (ABC) based on comprehensive circulating tumor DNA analysis and association with clinical outcomes in the Phase III MONALEESA-7 trial (2019) (1)
Initial Treatment of Patients with Primary Breast Cancer : Evidence , Controversies , Consensus Spectrum of Opinion of German Specialists at the 15 th International (2017) (1)
Health related quality of life in women with HR+/HER2- advanced or metastatic breast cancer treated in real world settings in Italy and Germany. (2018) (1)
Prognostic impact of local therapy of the primary tumor in metastatic breast cancer. (2012) (1)
Awareness and Availability of Routine Germline BRCA1/2 Mutation Testing in Patients with Advanced Breast Cancer in Germany (2021) (1)
Comparison of efficacy and safety of biosimilar filgrastim in a RCT (PIONEER) and real-world practice (MONITOR-GCSF). (2018) (1)
134TiP A phase III trial of nivolumab with neoadjuvant chemotherapy and adjuvant endocrine therapy in ER+/HER2− primary breast cancer: CheckMate 7FL (2020) (1)
Neoadjuvant therapy in patients with triple negative and HER2 positive early breast cancer (2017) (1)
Abstract P2-10-03: Genomic markers but not molecular subtypes provide prognostic impact and predict anthracycline efficacy in early triple-negative breast cancer: Results from the prospective WSG PlanB trial (2018) (1)
[Breast cancer in male]. (2017) (1)
0058 Determination of ASCO recommended prognostic factors uPA/PAI-1 in clinical routine and the node-negative NNBC 3-Europe therapy trial (2009) (1)
Molecular subtypes, body mass index (BMI), and their time-varying prognostic impact in node-positive breast cancer (BC): Pooled analysis from the WSG AM-01 and -02 trials. (2011) (1)
Abstract P1-13-02: Analysis of the NNBC 3-Europe trial: Addition of docetaxel to anthracycline containing adjuvant chemotherapy in high risk node-negative breast cancer patients. (2012) (1)
Preservation of Biomaterials for translational research in current breast cancer studies: Review and recommendations (2007) (1)
[Possibilities in immunocytochemistry exemplified by bone marrow aspiration cytology in patients with breast carcinoma]. (1990) (1)
Effects of chemotherapy on olfactory function in breast cancer patients (2008) (1)
Abstract P5-19-01: Impact of palbociclib plus letrozole on patient-reported general health status compared with letrozole alone in ER+/HER2- advanced/metastatic breast cancer (2018) (1)
Performance of neural nets, CART, and Cox models for censored survival data (1999) (1)
Correlation between work productivity loss (WPL) and European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ-C30) domains from the MONALEESA-7 (ML-7) trial of premenopausal women with HR+/HER2- advanced breast cancer (ABC). (2021) (1)
PO103 IMPROVING PALLIATIVE CARE IN CLINICAL ROUTINE: IN-HOUSE TRAINING OF PALLIATIVE MEDICINE AND ITS EFFECTS AND EVALUATION IN A BREAST AND GYNECOLOGICAL CENTER OF A CCC (2013) (1)
HER2-positive breast cancer: neoadjuvant and adjuvant therapy (2016) (1)
Impact of Etoposide on BRCA1 Expression in Various Breast Cancer Cell Lines (2017) (1)
P70 The ADEBAR-trial — participation in a randomized phase III study (evaluating the role of adjuvant docetaxel in high-risk breast cancer patients) improves treatment strategies and individual patient care in recruiting centers (2005) (1)
Impact of MammaPrint and BluePrint on early breast cancer treatment decisions: WSG PRIMe study results (2017) (1)
Abstract P5-07-03: Prosigna® results impact on adjuvant decision making in early breast cancer (EBC): Final analysis of the prospective WSG study (2016) (1)
44O Pembrolizumab (pembro) vs chemotherapy (chemo) for previously treated metastatic triple-negative breast cancer (mTNBC): KEYNOTE-119 Asia-Pacific subpopulation (2020) (1)
The ADEBAR trial: Final toxicity analysis of a phase III study evaluating the role of docetaxel in the adjuvant therapy of breast cancer patients with extensive lymph node involvement (2007) (1)
3O Mutation analysis of circulating tumour DNA from baseline and study discontinuation samples in SANDPIPER, a phase III study of taselisib or placebo with fulvestrant in oestrogen receptor-positive, human epidermal growth factor receptor 2-negative, PIK3CA-mutant advanced breast cancer (2020) (1)
Report of toxicities from the multicenter, randomized NNBC 3-Europe trial: 6xFEC versus 3xFEC-3xDoc for high-risk node-negative breast cancer patients. (2010) (1)
Comparative biomarker analysis of PALOMA-2/3 trials for palbociclib (2022) (1)
Final multivariate analysis of obesity and survival in patients with node-positive primary breast cancer: The ADEBAR trial. (2011) (1)
Abstract P2-10-05: eHealth in modern breast cancer treatment: New possibilities in communication between patients, doctors and nursing staff (2015) (1)
Incremental costs of chemotherapy—Pharmacoeconomic results from the prospective adjuvant AGO-WSG intergroup EC->DOC trial comparing an anthracycline-docetaxel sequence to CMF in node-positive breast cancer (2008) (1)
Results of the German fulvestrant in practice evaluation programme to evaluate the efficacy, safety, tolerability and acceptance of fulvestrant under daily routine conditions. (2009) (1)
Abstract 4209: First-line doublet chemotherapy for mTNBC: circulating tumor cell analysis of the tnAcity trial (2018) (1)
91O Pooled analysis of patient (pt)-reported outcomes (PROs) in the MONALEESA (ML)-2, -3, and -7 trials: Additional results and key subgroup findings (2021) (1)
Abstract OT1-08-09: CONTESSA: A multinational, multicenter, randomized, phase 3 registration study of tesetaxel plus a reduced dose of capecitabine in patients with HER2-, hormone receptor + (HR+) metastatic breast cancer (MBC) who have previously received a taxane (2020) (1)
Abstract P1-06-06: No age-related outcome disparities according to 21-gene recurrence score groups in early breast cancer patients treated by adjuvant chemotherapy in the prospective WSG PlanB trial (2018) (1)
Immunohistochemical correlation of thyroid hormone receptors (TR), retinoid x receptor (RXR), peroxisome proliferators-activated receptor (PPAR), the vitamin D receptor (VDR) and estrogen-/progesterone receptor (ER/PR) in breast carcinoma (2012) (1)
First data from the the Patient's Anastrozole Compliance to Therapy Programme evaluating the influence of a standardized information service on compliance in postmenopausal women with early breast cancer. (2016) (1)
353TiP HER2CLIMB-02: A randomized, double-blind, phase III study of tucatinib or placebo with T-DM1 for unresectable locally advanced or metastatic HER2+ breast cancer (2020) (1)
Abstract OT2-01-01: Randomized, double-blind, phase 3 study of tucatinib or placebo in combination with T-DM1 for subjects with unresectable locally-advanced or metastatic HER2+ breast cancer (2020) (1)
P5-18-03: First Interim Toxicity Analysis of the Randomized Phase III WSG Plan B Trial Comparing 4xEC-4xDoc Versus 6xTC in Breast Cancer Patients with HER2 Negative Breast Cancer (BC). (2011) (1)
Contessa: A multinational, multicenter, randomized, phase 3 registration study of tesetaxel in patients (Pts) with HER2-, hormone receptor + (HR+) locally advanced or metastatic breast cancer (MBC). (2018) (1)
Abstract OT-28-01: HER2CLIMB-02: A randomized, double-blind, phase 3 study of tucatinib or placebo with T-DM1 for unresectable locally-advanced or metastatic HER2+ breast cancer (2021) (1)
[Breast cancer - a modern approach in oncoplastic surgery]. (2019) (1)
Abstract P2-09-14: Evidence for Predictive and Prognostic Impact of Molecular Classification in Taxane-Based Chemotherapy in Intermediate Risk Breast Cancer — An Analysis of the WSG EC-Doc Trial: (2010) (1)
CONTESSA: A multinational, multicenter, randomized, phase III registration study of tesetaxel plus a reduced dose of capecitabine in patients (pts) with HER2-, hormone receptor + (HR+) locally advanced or metastatic breast cancer (LA/MBC) who have previously received a taxane. (2019) (1)
Is Routine Audiometric Evaluation Necessary in Gynaecologic Tumour Patients Undergoing Chemotherapy? (2013) (1)
Advances in Breast Cancer Treatment (2007) (1)
2MO Abemaciclib in high risk early breast cancer (2020) (1)
Abstract P4-15-01: Distinct early proliferation response to neoadjuvant anti-HER2 antibody drug conjugate +/- endocrine therapy in early breast cancer in the WSG ADAPT HER2+/HR+ trial (2015) (1)
Increased risk for thromboembolic events from combination of a gynecologic malignancy with severe acute respiratory syndrome coronavirus 2 infection: a case report (2022) (1)
ABC5 International Consensus Conference on Advanced Breast Cancer, Lisbon, 16 November 2019 (2020) (1)
Filariasis of the Axilla in a Patient Returning from Travel Abroad: A Case Report (2012) (1)
Early prediction of efficacy of endocrine therapy in breast cancer (BC): Pilot study and validation with 18F fluoroestradiol (18F-FES) PET/CT. (2013) (1)
Abstract PD5-10: Impact of immune markers on response to neoadjuvant de-escalated T-DM1 or trastuzumab with/or without endocrine therapy in HR+/HER2+ early breast cancer: A translational subproject of the WSG-ADAPT-HER2+/HR+ trial (2020) (1)
Cytoplasmic PPARγ is a marker of poor prognosis in patients with Cox-1 negative primary breast cancers (2020) (1)
Abstract GS1-09: Abemaciclib plus endocrine therapy for HR+, HER2-, node-positive, high-risk early breast cancer: results from a pre-planned monarchE overall survival interim analysis, including 4-year efficacy outcomes (2023) (1)
20 Impact of fulvestrant 500 mg/month versus fulvestrant 250 mg/month on bone turnover markers and endometrial thickness: findings from the NEWEST study (2010) (1)
PRECYCLE: Impact of CANKADO-based eHealth-support on quality of life in metastatic breast cancer patients treated with palbociclib and endocrine therapy (2019) (1)
Update 2010 of the German AGO Recommendations for the Diagnosis and Treatment of Early and Metastatic Breast Cancer – Chapter A: Surgery, Pathology and Prognostic Factors, Adjuvant and Neoadjuvant Therapy, Adjuvant Radiotherapy (2010) (1)
Chemotherapy (CT) decision in patients (pts) with node-positive (N plus ), ER plus , early breast cancer (EBC) in the wake of new ASCO guideline - A different take on the evidence for the 21-gene recurrence score (RS) assay (2017) (1)
PLASMINOGEN ACTIVATOR SYSTEM IN BREAST CANCER TISSUE AND BLOOD : CLINICAL RELEVANCE AND METHODOLOGICAL CONSIDERATIONS (1998) (1)
CLRM-14. OPEN-LABEL, MULTINATIONAL, MULTICENTER, PHASE 3B/4 STUDY OF TRASTUZUMAB DERUXTECAN (T-DXD) IN PATIENTS WITH OR WITHOUT BASELINE BRAIN METASTASIS (BM) WITH PREVIOUSLY TREATED ADVANCED/METASTATIC HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2–POSITIVE BREAST CANCER (HER2+ BC): DESTINY-BREAST12 (2021) (1)
Cutting-Edge Therapy Concepts - Cure Metastatic Breast Cancer? (2014) (1)
Obesity and disease-free survival in patients with nodal-positive early-stage breast cancer: The ADEBAR trial. (2010) (1)
S22ERA-Net TRANSCAN JTC 2011: Critical aspects of the startup procedures of an International Academic Clinical trial (ET-FES), funded by the European Community (EC) and coordinated by an Italian Institution. (2016) (1)
PD07-01: Sequential Treatment with Epirubicin/Cyclophosphamide, Followed by Docetaxel vs. FEC120 in the Adjuvant Treatment of Breast Cancer Patients with Extensive Lymph Node Involvement: Final Survival Analysis of the German ADEBAR Phase III Study. (2011) (1)
Treatment and outcome in metastatic lobular breast cancer in the prospective German research platform OPAL (2023) (1)
257OINTENSE DOSE-DENSE EPIRUBICIN (E), PACLITAXEL (T), CYCLOPHOSPHAMIDE (C) (IDDETC) IS HIGHLY EFFECTIVE IN ADJUVANT THERAPY OF NODE-POSITIVE BREAST CANCER PATIENTS (PTS). AN ANALYSIS OF THE GBG, AGO-B, AND NOGGO STUDY GROUPS. (2014) (1)
Post-Neoadjuvant Gemcitabine and Cisplatin with Regional Hyperthermia for Patients with Triple-Negative Breast Cancer and Non-pCR after Neoadjuvant Chemotherapy: A Single-Institute Experience (2020) (1)
A look at current and potential treatment approaches for hormone receptor‐positive, HER2‐negative early breast cancer (2022) (1)
Abstract PD10-11: Keyriched-1- A prospective, multicenter, open label, neoadjuvant phase ii single arm study with pembrolizumab in combination with dual anti-HER2 blockade with trastuzumab and pertuzumab in early breast cancer patients with molecular HER2-enriched intrinsic subtype (2022) (1)
The Future of Breast Cancer Management (2008) (1)
Abstract OT1-12-04: A phase 3, open-label trial of neoadjuvant trastuzumab deruxtecan (T-DXd) monotherapy or T-DXd followed by THP compared with ddAC-THP in patients with high-risk HER2-positive early-stage breast cancer (DESTINY-Breast11) (2022) (1)
Impact of stromal tumor-infiltrating lymphocytes (sTILs) on response to neoadjuvant chemotherapy in triple-negative early breast cancer in the WSG-ADAPT TN trial (2022) (1)
Comparison of predictive and prognostic impact of molecular subtypes and central grade regarding taxane-based therapy in intermediate-risk breast cancer: Results from the EC-Doc trial. (2011) (1)
Abstract HER2-18: HER2-18 Determination of HER2-low status in tumors of patients with unresectable and/or metastatic breast cancer in DESTINY-Breast04 (2023) (1)
E6. Can an international consensus meeting change the future of advanced breast cancer patients? Highlights from ABC1 Consensus Meeting (2012) (1)
Abstract P6-09-08: COMPliance and Arthralgia in Clinical Therapy: The COMPACT trial, assessing the incidence of arthralgia, therapy costs and compliance within the first year of adjuvant anastrozole therapy (2012) (1)
Breast cancer: increasing therapy options for HER2-positive early breast cancer (2012) (1)
ERANET JTC 2011: Submission and Activation of an International Academic Translational Project in Advanced Breast Cancer. Experience From the ET-FES Study (2022) (1)
Abstract P2-06-02: Health Economic Impact of Risk Group Selection According to ASCO-Recommended Biomarkers uPA/PAI-1 in Node-Negative Primary Breast Cancer (2010) (1)
Participation in study improves treatment strategies and individual patient care in the participating centres (2005) (1)
The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group (2021) (1)
PCN28 CYCLIN-DEPENDENT KINASE 4/6 INHIBITORS (CDK4/6I) IN HORMONE RECEPTOR-POSITIVE/HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE (HR+/HER2-) ADVANCED/METASTATIC BREAST CANCER (A/MBC): A SYSTEMATIC LITERATURE REVIEW OF REAL-WORLD EVIDENCE (RWE) STUDIES (2020) (1)
Level-I evidence for prognostic impact of UPA and PAI-1 in node-negative breast cancer patients: Ready for use in clinical routine (2003) (1)
Psychosocial Interaction from the Patients Point of View – Patient Satisfaction by CPQ-BC (Cologne Patient Questionnaire – Breast Cancer) in 51 German Breast Centers. (2009) (1)
Abstract P1-10-01: A randomized, double-blind trial to compare the efficacy and safety of proposed biosimilar pegfilgrastim (LA-EP2006) with reference pegfilgrastim in patients with breast cancer (PROTECT1) (2016) (1)
Disease-specific guidelines: a concept of facilitating early integration of palliative care into breast cancer therapy (2011) (1)
Abstract OT3-04-03: KEYNOTE-756: A randomized, double-blind, phase III study of pembrolizumab versus placebo in combination with neoadjuvant chemotherapy and adjuvant endocrine therapy for high-risk early-stage ER+/HER2–breast cancer (2019) (1)
Editorial Board / Contents / Imprint (2016) (0)
406 Morphological features of MR mammography in HER2-overexpressed breast cancer patients (2010) (0)
IN16 Advanced breast cancer: Advances in targeted therapy (2012) (0)
Update Breast Cancer 2022 Part 3 – Early-Stage Breast Cancer (2022) (0)
PCN4 Overall Survival in Post-Menopausal Women with HR+/HER2- Advanced Breast Cancer Receiving a CDK 4 and 6 Inhibitor + Fulvestrant after Progressing on/after Prior Endocrine Therapy: A Fractional Polynomial Network Meta-Analysis (2020) (0)
Gastrointestinal symptoms & health-related quality of life among women with HR+/HER2- advanced or metastatic breast cancer treated in real-world settings in Italy and Germany. (2019) (0)
PD06-07: COMPliance and Arthralgias in Clinical Therapy (COMPACT): Assessment of the Incidence and Severity of Arthralgia, Treatment Costs and Compliance within the First Year of Adjuvant Anastrozole Therapy. (2011) (0)
P087 Endocrine sensitivity is decisive for patient outcome in small PN0 breast cancers (PT1A,b) (2015) (0)
Impact of stromal tumor-infiltrating lymphocytes (sTILs) on response to neoadjuvant chemotherapy in triple-negative early breast cancer in the WSG-ADAPT TN trial (2022) (0)
Abstract P4-01-01: Presence of circulating tumor cells in high-risk early breast cancer do not predict site of metastatic lesions - Results of the SUCCESS A trial (2020) (0)
PTK7 Expression in Triple-negative Breast (2013) (0)
Tumor-associated proteolytic factors uPA and PAI-1: clinical relevance and promising targets for therapy (2001) (0)
Pembrolizumab vs placebo + chemotherapy as neoadjuvant treatment, followed by pembrolizumab vs placebo as adjuvant treatment for early triple-negative breast cancer (TNBC): Phase 3 KEYNOTE-522 study (2022) (0)
Contents, Vol. 35, Supplement 1, 1995 (1995) (0)
NEWEST: Neoadjuvant randomized study to comparison of Fulvestrant in 2 dosages for treatment of local advanced breast cancer (2008) (0)
Abstract P2-11-04: Efficacy and safety of darbepoetin alfa or epoetin beta in 2994 high risk early breast cancer patients participating in the German adjuvant intergroup node-positive study (GAIN) (2017) (0)
San Antonio Report 2005: Diagnostics, Detection, Proteomics, Nanotechnology, Pathology, Operative Techniques (2006) (0)
Abstract P3-13-02: Surcigal management of ipsilateral breast tumor recurrence (2016) (0)
SOFIA: Phase II study of neoadjuvant epirubicin, cyclophosphamide (EC) plus sorafenib (S) followed by paclitaxel (Pw) plus sorafenib (S) in women with primary breast cancer (BC; GBG 45). (2011) (0)
166P Awareness and availability of routine germline BRCA1/2 (gBRCA1/2) mutation testing in patients (pts) with advanced breast cancer (ABC) in Germany (2020) (0)
THE BISPHOSPHONATE COMPLIANCE PROTOCOL – A STUDY TO DETERMINE INFLUENCE FACTORS AND IMPACT OF NONCOMPLIANCE AND NON-ADHERENCE UNDER BISPHOSPHONATE THERAPY (2009) (0)
F11 Evidence in favor of taxane based combinations and no anthracycline in adjuvant and metastatic settings (2009) (0)
Jointly Improving Women’s Health Worldwide – Current Focus of the ‘International Working Group’ of the German Society of Obstetrics and Gynaecology (AG FIDE) (2009) (0)
With or Without Chemotherapy (2010) (0)
18P Relevance and Prediction of Breast Cancer Phenotype in Primary Tumor and its Positive Lymph Nodes and Later Disease Recurrence (Metastatic Breast Cancer): Results of the Primet-Trial (WSG / Detect) (2012) (0)
Interaction of PAFAH and beta-catenin in BRCA1 mutant breast cancer (2020) (0)
Awareness and Availability of Routine Germline <b><i>BRCA1/2</i></b> Mutation Testing in Patients with Advanced Breast Cancer in Germany (2021) (0)
Multiple PIK3CA mutation clonality correlates with outcomes in taselisib + fulvestrant-treated ER+/HER2–, PIK3CA-mutated breast cancers (2023) (0)
Contents Vol. 33, 2010 (2010) (0)
Abstract PS10-28: Neratinib as extended adjuvant therapy in patients with HER2-positive/HR-positive early breast cancer: HTA-driven analyses from the ExteNET study (2021) (0)
Diagnostic effectiveness of [18F]Fluoroestradiol PET/CT in oestrogen receptor-positive breast cancer: the key role of histopathology. Evidence from an international multicentre prospective study. (2023) (0)
Late Presentation at Primary Diagnosis of Breast Cancer: Patients’ Personality Characteristics and Attitudes (2020) (0)
Contents, Vol. 31, Supplement 2, 1991 (1991) (0)
Abstract P3-13-07: Does treatment response to new agents differ between visceral and non-visceral metastatic breast cancer: A systematic literature review of registration trials (2015) (0)
Higher PAI-1 levels in lymph node metastases than in corresponding primary tumor tissue correlate significantly with poor patient outcome in breast cancer. (2003) (0)
Overview of neoadjuvant endocrine therapy for receptor positive breast cancer in post menopausal women (2004) (0)
Abstract P5-11-05: Influence of Demographic and Histopathological Characteristics on Compliance and Persistence in 4.923 Postmenopausal Women with Early Breast Cancer (EBC) - Results of the Patient's Anastrozole Compliance to Therapy Programme (PACT) (2010) (0)
664 Flow cytometrically determined S-phase fraction is a stronger prognostic factor in node-negative breast cancer than immunohistochemically detected MIB1 (KI-67) (1995) (0)
Abstract P4-06-22: Persistent Triple-Negative Phenotype Is Associated with Poorest Outcome among Patients with Metastatic Breast Cancer (BC) - Results of the Retrospective MulticenterPriMetStudy Comparing Molecular BC Phenotypes in Primary Tumors and Corresponding Recurrences: (2010) (0)
Can prognostic factors be used to reduce treatment intensity of screen detected breast cancer (2004) (0)
Association of T- and B-cell receptor repertoires with molecular subtypes and outcome in HER2+ breast cancer: An analysis of the NeoALTTO clinical trial. (2020) (0)
Abstract OT-30-01: KEYLYNK-009: A phase 2/3, open-label, randomized study of pembrolizumab plus olaparib vs pembrolizumab plus chemotherapy after induction with first-line pembrolizumab plus chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC) (2021) (0)
Benefit from participation in clinical trials (2006) (0)
Abstract P2-09-03: Identifying clinically relevant subgroups of women with HER2-positive breast cancer: An analysis of Neo-ALTTO using the 41-gene TRAR score (2018) (0)
Contents Vol. 6, 2011 (2011) (0)
Abstract P2-07-01: Association of TILs with clinical parameters, recurrence score, and prognosis in patients with early HER2-negative breast cancer (BC) – A translational analysis of the prospective WSG planB trial (2016) (0)
Adjuvant abemaciclib for high-risk early breast cancer (EBC): Factors increasing the rate of treatment discontinuations in monarchE. (2022) (0)
Meetings and Conferences (2014) (0)
Metastatic Breast Cancer: Is There a Differential Therapy Efficacy between Visceral and Non-Visceral Metastatic Breast Cancer? (2019) (0)
Commentary by the German panel of experts on the ABC5 voting results (2020) (0)
Prognostic impact of androgen receptor (AR) and forkhead box A1 (FOXA1) in early HER2-negative primary breast cancer: A translational substudy of the prospective phase III WSG-PlanB-trial. (2016) (0)
Abstract P2-13-01: Effects of 12-Week Resistance Training on Strength, Fatigue Syndrome and Quality of Life with Breast Cancer Patients during Chemotherapy (2010) (0)
PO75 RETROSPECTIVE ANALYSIS OF ADVANCED LUMINAL BREAST CANCER PATIENTS TREATED WITH ENDOCRINE THERAPY (ET) ANDPALBOCICLIBWITHINACOMPASSIONATE USE PROGRAMME (2017) (0)
P44 Is tumor-biological risk-assessment realistic in node-negative breast cancer? A status report of the ongoing clinical multicenter trial NNBC-3-Europe (2007) (0)
CURRENT STANDARDS OF CARE IN HR+ HER2– ABC (2021) (0)
Review of the monarchE trial suggests no evidence to support use of adjuvant abemaciclib in women with breast cancer - Authors' reply. (2023) (0)
140 Combinations of endocrine agents and new targeted drugs: where do we stand? (2009) (0)
Patient's Anastrozole Compliance to Therapy Programme (PACT) – Influence of the addition of a standardized information and reminder service on compliance in comparison to standard clinical care alone in women with early breast cancer (2007) (0)
Subject Index Vol. 3, 2008 (2008) (0)
Protroca: a non-interventional study on prophylaxis of chemotherapy induced neutropenia using Lipegfilgrastim in non-selected breast cancer patients (2019) (0)
Treatment Landscape of Ductal Carcinoma In Situ. (2021) (0)
MoCo – an image-based retrospective study assisted by electronic image management – an implemented solution at Munich Technical University (2008) (0)
Supplementary Material for: Factors Influencing Decision-Making for or against Adjuvant and Neoadjuvant Chemotherapy in Postmenopausal Hormone Receptor-Positive Breast Cancer Patients in the EvAluate-TM Study (2016) (0)
DNA methylation marker and prediction of outcome in node-positive, estrogen-receptor positive breast cancer patients receiving adjuvant anthracyclin-based chemotherapy (2008) (0)
Prevalence of risk factors for QT prolongation and torsades de pointes among women with HR+/HER2- advanced or metastatic breast cancer treated in real-world settings in Italy and Germany. (2019) (0)
From genomic data analysis to drug development: a new generation of trials using molecular marker assessment in breast cance. (2014) (0)
’ s response to reviews Title : Impact of uPA / PAI-1 and disseminated cytokeratin-positive cells in breast cancer (2019) (0)
ARandomized, Double-Blind, Phase II Study of Two Doses of Pemetrexed as First-Line Chemotherapy forAdvanced Breast Cancer (2007) (0)
P180 Molecular types, uPA/PAI-1, clinical and pathological features in node-negative breast cancer: Distribution within the clinical trial NNBC 3-Europe compared to a single-institution cohort (2011) (0)
HER2 status and UPA/PAI-1 provide complementary information on patient outcome in node-negative breast cancer (2003) (0)
Prospective cost analysis from the provider's perspective: pharmaco-economic results from AGO-WSG intergroup adjuvant EC→DOC trial vs. CMF in nodal-positive breast cancer and its reimbursement. (2009) (0)
Abstract OT2-16-02: Open-label, phase 3b/4 study of trastuzumab deruxtecan (T-DXd) in patients with or without baseline brain metastasis with advanced/metastatic human epidermal growth factor receptor 2–positive breast cancer: DESTINY-Breast12 (2023) (0)
Safety profile of EP2006 biosimilar filgrastim: A combined analysis of two independent phase III studies. (2017) (0)
Adjuvant Therapies for Breast Cancer Improve Cure Rates but Appear to Shorten Post-Metastatic Survival (2017) (0)
CANKADO: First open eHealth platform for Oncology (2016) (0)
The benefit using an integrated electronical study platform for a presurgical therapy trial (HEDON) in primary breast cancer (2008) (0)
Abstract TC1-3-1: Ki 67 Ki67 – a clinically relevant biomarker or just nice to have information? (2023) (0)
Luminal Metastatic Breast Cancer: Best Sequence of Available Therapies (2017) (0)
Process for the treatment of proliferative disorders mammary cells. (2003) (0)
Neratinib as extended adjuvant therapy in patients with HER2-positive/HR-positive early breast cancer: German HTA-driven analyses from the ExteNET study (2021) (0)
Results of the German IPEP study evaluating tolerability, efficacy and acceptance of fulvestrant under routine clinical conditions in advanced breast cancer (2008) (0)
172P Gene expression in early breast cancer (EBC) patients (pts) with relapse despite pathologic complete response (pCR): An intra- and interindividual (matched control) analysis (2020) (0)
Molecular basis and possibilities for modulation of resistance to anti-HER2 therapy (2008) (0)
SP171 Prognostic and predictive signatures in breast cancer: update and future perspectives (2009) (0)
Abstract PD12-06: Treatment-related amenorrhea with T-DM1 plus pertuzumab (KP) is lower than with docetaxel/carboplatin/trastuzumab/pertuzumab (TCHP) in the phase III neoadjuvant KRISTINE trial (2021) (0)
Results of multicenter phase II WSG Neo-Predict trial: Predictive markers for evaluation of response to neoadjuvant paclitaxel+trastuzumab+lapatinib in HER2-positive early breast cancer. (2017) (0)
Impact of RNA Signatures on pCR and Survival after 12-Week Neoadjuvant Pertuzumab plus Trastuzumab with or without Paclitaxel in the WSG-ADAPT HER2+/HR− Trial (2022) (0)
175P Real-world patient and practice characteristics associated with use of CDK4/6 inhibitors among patients receiving first therapy for HR+/HER2- advanced or metastatic breast cancer in Italy and Germany (2020) (0)
[Prognostic factors in carcinoma of the breast. Thereupon depends success of the treatment]. (2003) (0)
P157 Life satisfaction and biographic changes in young breast cancer survivors (2015) (0)
The ADEBAR-trial: Effect of participation in a randomized phase III study (evaluating the role of adjuvant docetaxel in high-risk breast cancer patients) on treatment strategies and individual patient care in recruiting centers. (2004) (0)
P62 Sequencing of regional radiotherapy andchemotherapy does not compromise cytotoxic dose intensity in the ADEBAR-trial (2005) (0)
412TiPTNACITY: A PHASE II/III TRIAL OF NAB-PACLITAXEL (NAB-P) PLUS EITHER GEMCITABINE (GEM) OR CARBOPLATIN (CARBO) VS GEM/CARBO AS FIRST-LINE TREATMENT FOR TRIPLE-NEGATIVE METASTATIC BREAST CANCER (TNMBC). (2014) (0)
DNA-methylation markers and YB-1 as indicators of therapy response in breast cancer (2006) (0)
ADEBAR study, a phase III study on the assessment of the role of docetaxel in the adjuvant treatment of patients with high-risk nodal-positive breast cancer: conclusive toxicity data (2007) (0)
Substantial ninety-nine percent reduction of turnaround time for QTc diagnostics using smartphone-based tele-cardiology. (2020) (0)
DIBH radiotherapy in left-sided breast cancer patients using an optical surface scanning system (2017) (0)
P75 Current status and results of the second toxicityanalysis of a WSG/AGO-Mamma Intergroup Phase III trial AM02 “Ec->Doc” for patients with primary breast cancer and 1-3 positive axillary lymph nodes (2005) (0)
495 Isolation of competent ovarian carcinoma cells from fresh tumor tissue by a magnetic separation system (MACS) (1995) (0)
11 Everolimus (Rad001) as Treatment in Breast Cancer Patients with Bone Metastases Only – First Results of the Multi-centre, Placebo-controlled, Randomized Discontinuation Phase II RADAR Study (2012) (0)
Subject Index Vol. 24, 2003 (2004) (0)
Elderly patients do benefit from eHealth support (2017) (0)
evaluation of the impact of a three month resistance training on fatigue and biomarkers of breast cancer patients during chemotherapy : Id 353 (2014) (0)
Meetings and Conferences · Tagungen und Kongresse (2012) (0)
Hierarchical neural net technology for molecular staging with clinical data (2006) (0)
Long-term prognostic impact of risk classifications in node-negative breast cancer – comparison between Adjuvant!, St. Gallen, and a novel risk algorithm used in the prospectively randomized Node-Negative-Breast-Cancer-3 trial (NNBC-3) (2008) (0)
Hormone Receptor and HER2 Status Switch in Non-pCR Breast Cancer Specimens after Neoadjuvant Therapy (2022) (0)
Differential impact of prognostic parameters in hormone receptor-positive lobular early breast cancer in the WSG PlanB trial (2020) (0)
Adjuvant Therapy for Elderly Breast Cancer Patients after Breast-Conserving Surgery: Outcomes in Real World Practice (2023) (0)
Controversies in routine clinical management and research priorities for young breast cancer patients (2016) (0)
Flow cytometric analysis of fresh human tumor tissue: A new separation system for identification of single tumor cells and application to analysis of tumor-asssociated proteases (1993) (0)
Adjuvant Antibody Therapy with Trastuzumab in Early Breast Cancer (2006) (0)
PD-0180: Interim Report from the SAVE HEART Study: deep inspiration breath-hold in left-sided breast cancer (2020) (0)
Abstract P1-07-03: Unmet needs and future applications of breast cancer multigene signatures in routine clinical practice: results from the European PROCURE Project (2023) (0)
EP3 (prostaglandin E2 receptor 3) expression is a prognostic factor for progression-free and overall survival in sporadic breast cancer (2018) (0)
[Results of the EORTC/NCI Expert Meetings "HER2 diagnosis"]. (2002) (0)
Evaluation of risk factor-questionnaire for osteoporosis in breast carcinoma patients (2009) (0)
Indications to neoadjuvant chemotherapy and tailored strategies (2018) (0)
Primary outcome analysis of invasive disease-free survival for monarchE: abemaciclib plus adjuvant endocrine therapy for high-risk early breast cancer (2021) (0)
1671MO Provision of palliative care for patients with cancer and SARS-CoV-2 infection (2020) (0)
Practice-Changing Perspectives regarding Systemic Therapy in Early Breast Cancer: Opinions of German Experts regarding the 17th St. Gallen International Consensus Conference (2022) (0)
Contents Vol. 3, 2008 (2008) (0)
De-Escalated Neoadjuvant Trastuzumab-Emtansine With or Without Endocrine Therapy Versus Trastuzumab With Endocrine Therapy in HR+/HER2+ Early Breast Cancer: 5-Year Survival in the WSG-ADAPT-TP Trial. (2023) (0)
Activator Inhibitor Type 1 (n = 3424) Urokinase-type Plasminogen Activator (uPA) and Plasminogen Cancer Patients Classified High-Risk according to Enhanced Benefit from Adjuvant Chemotherapy in Breast (2013) (0)
Abstract P5-10-09: Comparison of the (Non-)Hematological Toxicity and Compliance of Different Anthracycline Containing Regimen with the Standard AC/EC in Elderly Patients with Primary Breast Cancer (2010) (0)
Abstract P3-10-12: Pilot Phase of the Randomized PlanB Trial: Prospective Comparison of Molecular Classification, Oncotype DX® and Clinical-Pathological Characteristics in Hormone-Receptor (HR) Positive Primary Breast Cancer (2010) (0)
68TiP KEYLYNK-009: A phase II/III, open-label, randomized study of pembrolizumab (pembro) + olaparib (ola) vs pembro + chemotherapy after induction with first-line (1L) pembro + chemo in patients (pts) with locally recurrent inoperable or metastatic TNBC (2020) (0)
Editorial Board / Contents / Imprint (2016) (0)
The benefit using an integrated electronic trial platform for a neoadjuvant therapy trial (HEDON) in primary breast cancer – results of an evaluation study. (2009) (0)
New key markers and therapeutic subgroups in breast cancer resulting from molecular staging (2006) (0)
EP-1336: The role of adjuvant radiotherapy in male breast cancer patients in clinical practice (2018) (0)
Multigene Testing to Forgo Chemotherapy in Early Breast Cancer (2016) (0)
METHOD FOR TRAINING ANEURAL NETWORK 1. FIELD OF THE INVENTION (2017) (0)
PARP inhibitors: risk factors for toxicity and matching patients to the proper poly (ADP-ribose) polymerase inhibitor (PARPi) therapy (2023) (0)
Comprehensive cancer therapy in metastatic breast cancer- a pilot project of early integration of palliative medicine (2011) (0)
Vitamin D receptor status of circulating tumor cells (CTC) in metastatic breast cancer patients (2016) (0)
Abstract OT2-26-01: Open-label, multinational, multicenter, phase 3b/4 study of trastuzumab deruxtecan (T-DXd) in patients with or without baseline brain metastasis with previously treated advanced/metastatic human epidermal growth factor receptor 2-positive breast cancer (HER2+ BC): DESTINY-Breast1 (2022) (0)
Plasminogen activator (uPA) and its inhibitor (PAI-1) as Bio-marker for the risk calculation in node-negative mammacarcinoma - The current NNBC 3-Europe study (2008) (0)
Abstract PL06-03: Urokinase plasminogen activator system: A multifunctional drug target. (2011) (0)
SARS-CoV-2 omicron (B.1.1.529)-related COVID-19 sequelae in vaccinated and unvaccinated patients with cancer: results from the OnCovid registry (2023) (0)
Contents Vol. 7, 2012 (2012) (0)
Abstract P6-11-06: Correlation Comprehensive Geriatric Assessment (CGA) and Inflammation and Nutrition Parameters with Outcome Measures in the Phase III PELICAN Trial for Metastatic Breast Cancer (MBC) (2010) (0)
480 Evidence from the phase III AVADO study reveals no increase in tumour malignant potential following treatment of metastatic breast cancer (mBC) with bevacizumab (BV) and docetaxel (D) (2010) (0)
Breast Cancer Molecular Testing for Prognosis and Prediction (2016) (0)
P231 Luminal subtypes vs. early Ki-67 response and Oncotype DX® in early breast cancer: WSG-ADAPT study (2015) (0)
A Special Key for Unlocking the Door to Targeted Therapies of Breast Cancer (2008) (0)
The patient experience (vol 105, Suppl 1, pg 91, 2007) (2008) (0)
Bisphosphonates in adjuvant treatment of early breast cancer. (2010) (0)
[Prognostic significance of the S-phase and MIB1 (Ki-67) proliferation parameters in node-negative breast carcinoma]. (1995) (0)
Patient satisfaction with scalp cooling for prevention of chemotherapy-induced alopecia in breast cancer patients: results from EVAScalp (2019) (0)
Reduction of Serious Adverse Events (SAE) under palbociclib treatment in patients using an interactive eHealth system (2020) (0)
Abstract P4-12-03: Assessment of quality of life (QoL) in patients with metastatic breast cancer (MBC) in clinical practice: A real-world multi-country survey (2022) (0)
YB-1 expression and effectiveness of different dose-intensification strategies in high-risk breast cancer: Five-year follow-up results of prospective randomized WSG-AM-01 trial (2007) (0)
Characterization of Vitamin D Receptor Expression in Breast Cancer Cells Lines (2015) (0)
Use of Granulocyte‐colony Stimulating Factor During Chemotherapy and Its Association With CA27.29 and Circulating Tumor Cells—Results From the SUCCESS A Trial (2018) (0)
Fifteen Years of Breast Care (2021) (0)
Efficacyand Safety of Palbociclib (PAL) PUS Fulvestrant (F) by Geographic Region in Women with Endocrine-Resistant Hormone Receptor-Positive (HR+), Human Epiderman Growth Factor Receptor 2-Negative (HER2-) Advanced Breast Cancer (ABC) from Paloma-3 (2017) (0)
Abstract 701: The acute phase response identifies cancer patients with adverse outcomes from SARS-CoV-2 infection as quantified by the OnCovid Inflammatory Score (2021) (0)
Review of: Demethylation of urokinase promoter as a prognostic marker in patients with breast carcinoma (2004) (0)
Urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 for tumor-biological risk assessment in node-negative breast cancer patients – The multicenter trial NNBC 3-Europe (2008) (0)
AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2022. (2022) (0)
Impact of proteolytic factors on surgical success and survival in ovarian cancer (2005) (0)
IN10 SYSTEMIC THERAPY FOR INOPERABLE LOCALLY ADVANCED BREAST CANCER: OPTIMAL STRATEGIES AND THERAPIES (2013) (0)
European Breast Cancer Conference 12, October 2–3, 2020: Interview with the Chairs (2020) (0)
Abstract OT3-14-02: Impact of CANKADO-based eHealth-support on quality of life in metastatic breast cancer patients treated with palbociclib and endocrine therapy - Precycle (2020) (0)
Abstract P2-13-03: KEYRICHED-1 - A prospective, multicenter, open label, neoadjuvant phase II single arm study with pembrolizumab in combination with dual anti-HER2 blockade with trastuzumab and pertuzumab in early breast cancer patients with molecular HER2-enriched intrinsic subtype (2022) (0)
322P Prognostic factors for overall survival (OS) in patients with hormone receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer (HR+/HER2− ABC): Analyses from PALOMA-3 (2020) (0)
Correction to: Cytoplasmic LXR expression is an independent marker of poor prognosis for patients with early stage primary breast cancer (2021) (0)
Prognostic impact of weight change during chemotherapy. (2012) (0)
Chemotherapy (CT) decision in node-positive (N+), ER+, early breast cancer (EBC) after new ASCO Guideline – evidence for the 21-gene Recurrence Score (RS) assay (2017) (0)
Invasion F actors u PA/PAI-1 a nd H ER2 S tatus P rovide Independent a nd C omplementary I nformation o n P atient Outcome i n N ode-Negative B reast C ancer (2003) (0)
Abstract OT2-03-02: lidERA Breast Cancer: A phase III adjuvant study of giredestrant (GDC-9545) vs physician’s choice of endocrine therapy in patients with estrogen receptor+, HER2– early breast cancer (2023) (0)
Abstract PD12-11: Patient-reported outcomes from the Phase III IMpassion031 trial of neoadjuvant atezolizumab + chemotherapy in early triple-negative breast cancer (2021) (0)
Abstract P1-02-01: Comparing the efficacy of aromatase inhibitors vs tamoxifen in hormone receptor-positive, human epidermal growth factor receptor 2-negative early breast cancer: a systematic review and trial-level meta-analysis (2023) (0)
PROCURE European consensus on breast cancer multigene signatures in early breast cancer management (2023) (0)
Contents, Vol. 27, Supplement 2, 1987 (1987) (0)
Evaluation of the implementation of training control in a three-month high-intensity resistance training intervention with breast cancer patients undergoing chemotherapy (2017) (0)
Abstract P1-08-09: EGFR expression is associated with decreased response from HER2 targeted therapeutics in the neo-adjuvant setting in the NeoALTTO trial (2013) (0)
Abstract P5-02-03: Combined biomarker analysis for prediction of pathological complete response (pCR) after 12 weeks of pembrolizumab + trastuzumab + pertuzumab in HER2-enriched early breast cancer: Keyriched-1 trial (2023) (0)
Abstract P2-17-01: Therapy of advanced breast cancer for patients with hormone receptor-positive/HER2-negative and HER2-positive tumors is changing in real life: First results from the prospective, national research platform OPAL for patients with advanced breast cancer in Germany (2020) (0)
Bisphosphonate compliance protocoll - a study in compiling the influence factors and impact of non-compliance and non-adherence under bisphosphonate therapy (2009) (0)
The ADEBAR-trial: Effect of participation in a randomized phase III study (evaluating the role of adjuvant docetaxel in high-risk breast cancer patients) on treatment strategies and individual patient care in recruiting centers (2004) (0)
Abstract OT3-2-03: Prospective observational study of clinical outcomes for the NanoString® technologies Prosigna™ test by the West German Study Group (2015) (0)
Treatment patterns and clinical outcomes in ER+/HER2-metastatic breast cancer in German real world settings (2017) (0)
Concentrations of plasminogen activator inhibitor type1 (PAI-I) and urokinase-type plasminogen aktivator (uPA) in primary breast cancer (BC) tissue and corresponding axillary lymph node metastasis. (2009) (0)
Immunocytochemical detection of tumor cells in the bone marrow of breast cancer patients at the time of primary therapy (1987) (0)
PO46 Unmet needs and biographic changes among young breast cancer survivors (2014) (0)
Wednesday, 16 April 2008 12:30–14:30POSTER SESSIONBiological response and outcomePoster DiscussionDown regulation of angiogenesis antagonist EFEMP1 is associated with unfavourable prognosis in sporadic breast cancer patients (2008) (0)
Abstract P6-04-01: A pre-surgical, window of opportunity study comparing the novel oral SERD AZD9496 with fulvestrant in patients with newly diagnosed ER+ HER2- primary breast cancer (2020) (0)
248 Targeting Tumour–Stroma Interaction for Prevention of Metastasis (2012) (0)
Radiotherapy in Elderly Breast Cancer Patients (2020) (0)
Implementation of palliative care in German breast centers - a national questionnaire, interim results (2011) (0)
Can We Keep the ‘PROMISE’? (2011) (0)
The ADEBAR-trial: The sequencing of regional radiotherapy and chemotherapy does not influence cytostatic dose intensity (2005) (0)
Panel-guided personalized medicine in metastatic breast and gynecological cancer: First experiences at the Comprehensive Cancer Centre Munich and clinical relevant changes over time (2020) (0)
A27 Instructional Session: Breast cancer (2010) (0)
Update Breast Cancer 2022 Part 1 – Early Stage Breast Cancer (2022) (0)
SA 8.2 Current adjuvant and neoadjuvant approaches (2023) (0)
ASCO 2007: What Remains Important for Breast Cancer Systemic Therapy in the Routine Setting? (2007) (0)
Author response: Infrared molecular fingerprinting of blood-based liquid biopsies for the detection of cancer (2021) (0)
OP-ANNO180192 1634..1657 (2018) (0)
OPTIMAL ENDPOINTS FOR ABC CLINCAL TRIALS: CAN WE AIM FOR MORE? (2019) (0)
Detection of qualitatively different uPAR in tissue extracts of breast carcinomas Correlation to prognosis (1999) (0)
Abstract OT3-3-06: NeoEribulin: A Phase II, non-randomized, open-label, single-arm, multicenter, exploratory pharmacogenomic study of single agent eribulin as neoadjuvant treatment for operable Stage I-II HER2 non-overexpressing breast cancer. (2012) (0)
PR50 Life satisfaction among young breast cancer survivors (2014) (0)
DNAMethylationMarkers Predict Outcome in Node-Positive, Estrogen Receptor-Positive Breast Cancer with Adjuvant Anthracycline-Based Chemotherapy (2008) (0)
Adjuvant Docetaxel in Node-Negative Breast Cancer Patients: A Randomized Trial of AGO-Breast Study Group, German Breast Group, and EORTC-Pathobiology Group (2023) (0)
Abstract P1-11-01: eHealth in modern patient-caregiver-communication: High rate of modern media use in physicians as well as breast cancer patients (2013) (0)
164MO Impaired Ki67 response towards neoadjuvant endocrine therapy in luminal breast cancer is associated with mutations conferring endocrine resistance: WSG-ADAPT HR+/HER2- translational results (2020) (0)
CDK4/6 Inhibitors Expand the Therapeutic Options in Breast Cancer: Palbociclib, Ribociclib and Abemaciclib (2019) (0)
Y-BOX BINDING PROTEIN YB-1 IDENTIFIES HIGH-RISK PRIMARY BREAST CANCER PATIENTS BENEFITING FROM RAPIDLY CYCLED TANDEM HIGH-DOSE ADJUVANT CHEMOTHERAPY (2009) (0)
IN26 BIOPSY, REBIOPSY AND DEALING WITH DISCORDANT RESULTS IN ABC (2015) (0)
METHOD FOR DETERMINING COMPETING RISKS FIELD OF THE INVENTION (2017) (0)
Contents Vol. 11, 2016 (2016) (0)
PP11 Expression differences of proteolytic factors uPA, PAI-1, and seven kallikrein-related peptidases (KLK5, 6, 7, 8, 10, 11, 13) between primary tumor and omentum metastasis impact outcome in advanced ovarian cancer (2009) (0)
[The views of cancer out-patients on the impact of the COVID-19 pandemic]. (2022) (0)
Weekly versus 3-weekly docetaxel (D2) plus doxorubicin (D4) for first-line treatment of metastatic breast cancer (MBC). (2016) (0)
Interim safety analysis of a randomized phase III study evaluating pegylated liposomal doxorubicin (PLD) versus capecitabine as first-line chemotherapy for metastatic breast cancer (MBC): The PELICAN study (2008) (0)
Risk Assessment in Node-Negative Breast Cancer by the Invasion Factors (Urokinase-Type Plasminogen Activator) and Its Inhibitor PAI-1. Correlation to the Tumor Characteristics in the Prospective NNBC 3-Europe Trial. On Behalf of the NNBC-3 Trial Group (2009) (0)
Advanced Breast Cancer (2022) (0)
Retrospective analysis of toxicity in patients (pts) with liver metastases (mets) from phase 3 studies of trastuzumab emtansine (T-DM1) in pts with metastatic breast cancer (MBC). (2014) (0)
Editorial Board / Contents / Imprint / Guidelines for Authors (2015) (0)
‘Above All: We Want to Live, and Hope for Cure' (2010) (0)
Molecular types and prognostic markers uPA/PAI-1 for 2,497 early breast cancer patients in the multicenter, randomized NNBC 3-Europe trial. (2010) (0)
[Interview with private lecturer Dr. med. Nadia Harbeck, Munich. Prognostic markers guide therapy (interview by Jochen Aumiller)]. (2003) (0)
Contents of Forthcoming Issues · Themenvorschau (2008) (0)
Progression-specific genes identified in microdissected formalin-fixed and paraffin-embedded tissue containing matched ductal carcinoma in situ and invasive ductal breast cancers (2018) (0)
0185 High-dose fulvestrant (500 mg): Clinical evidence supporting potentially improved efficacy benefits in hormone receptor-positive (HR+) advanced breast cancer (ABC) (2009) (0)
Abstract P4-06-08: Consensus on the utility of breast cancer multigene signatures in routine clinical practice among European breast cancer specialists - 1st results of the PROCURE project (2022) (0)
eHealth Strategy for Elderly Patients (eStEP) (2016) (0)
Level differentials of proteolytic factors uPA, PAI-1 and human kallikreins (hK) 5,6,7,8,10,11,13 in primary ovarian carcinoma tissues and corresponding omentum metastases impact on disease outcome (2005) (0)
Abstract P1-11-01: Trastuzumab deruxtecan vs treatment of physician’s choice in patients with HER2-low unresectable and/or metastatic breast cancer: Subgroup analyses from DESTINY-Breast04 (2023) (0)
Abstract P6-03-08: Trained Artificial Intelligence (AI) for Predicting Treatment Termination Based on Patient Observations in Advanced Breast Cancer (2023) (0)
Using an integrated electronic trial platform for a presurgical therapy trial (HEDON) in primary breast cancer - One year of practical experience (2008) (0)
eHealth acceptance in breast cancer care (2016) (0)
Abstract P6-10-06: A preoperative window-of-opportunity study of imlunestrant in estrogen receptor-positive, HER2-negative early breast cancer: Results from the EMBER-2 study (2023) (0)
Non-compliance in adjuvant endocrinal treatment of breast cancer (2007) (0)
[Flow cytometry DNA analysis of pure cell nuclei from formalin fixed paraffin sections in primary breast cancer: correlation with other prognostic factors]. (1991) (0)
A Phase II Study of Metronomic Daily Oral Vinorelbine as First-Line Chemotherapy in Advanced/Metastatic Hormone Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Breast Cancer Resistant to Endocrine Therapy: Vinometro (2017) (0)
Gynecological Cancers: A Challenge of Individualized Therapy in the Adjuvant and Palliative Setting (2015) (0)
[The views of cancer out-patients on the impact of the COVID-19 pandemic]. (2022) (0)
eStEPs � A eHealth Strategy for Elderly Patients (Preprint) (2018) (0)
An Introduction to Breast Cancer Diagnosis, Prognosis, and Artificial Intelligence (2000) (0)
Predictive array analysis of breast cancer (2004) (0)
LKB1 and its importance for survival in EpCAM negative circulating tumor cells (CTC) in metastatic breast cancer. (2017) (0)
History of HER2/neu and development of trastuzumab (2009) (0)
Title Page / Contents Vol. 5, Supplement 1, April 2010 (2010) (0)
Abstract OT2-05-02: A phase II study of metronomic daily oral vinorelbine as first-line chemotherapy in advanced/metastatic hormone receptor positive (HR+) / human epidermal growth factor receptor 2 negative (HER2-) breast cancer resistant to endocrine therapy - VinoMetro (2018) (0)
Titel Page / Table of Contents (2008) (0)
Abstract P2-13-30: First interim analysis from ELEANOR: A multi-national, prospective, non-interventional study (NIS) in patients with human epidermal growth factor receptor positive (HER2+) early breast cancer observing real-life extended adjuvant treatment with neratinib (2022) (0)
Abstract P2-09-07: Low levels of HER2 extracellular domain (ECD) compared to intracelluar domain (ICD) in NeoALTTO may segregate benefit from lapatinib and trastuzumab in breast cancer (2018) (0)
Consensus on the utility of breast cancer multigene signatures in routine clinical practice: Results of the PROCURE Project. (2022) (0)
Critical analysis of care and payment within a DRG reimbursement system for primary breast cancer. (2010) (0)
Impact of Palbociclib plus Letrozole on Health Related Quality of Life (HRQOL) compared with Letrozole alone in first-line Postmenopausal Patients with ER+ HER2- Metastatic Breast Cancer (MBC): Results from PALOMA-2 Bone Metastases Subgroup (2018) (0)
Impact of proteolytic factors (uPA, PAI-I, tissue kallikreins) on surgical success and survival in ovarian cancer (2005) (0)
Challenges faced across borders to open European academic multicentre projects: The ET-FES program part of the ERA-Net TRANSCAN JTC 2011 (2017) (0)
[Hereditary breast and ovarian cancer. What to think about and what to do?] (2021) (0)
P5-17-02: Associations between Breast Cancer Patients' Satisfaction with Nursing Staff and Hospital Characteristics, Results of a German Multicenter Study. (2011) (0)
Title Page / Table of Contents / Imprint / Guidelines for Authors (2015) (0)
De-escalated neoadjuvant chemotherapy in early triple-negative breast cancer (TNBC): Impact of molecular markers and survival analysis of the WSG-ADAPT-TN trial. (2022) (0)
Abstract P2-01-01: Interim analysis (n=200) from ELEANOR: a multi-national, prospective, non-interventional study among patients with HER2+ and HR+ early breast cancer treated with extended adjuvant neratinib in the clinical routine (2023) (0)
Challenging tumour aggressiveness – Individualising patient management (2008) (0)
EP-1331: Role of postoperative radiotherapy in DCIS: an observational study of 1,048 cases (2018) (0)
P137 Sexuality, childbearing, parenting concerns – needs in young breast cancer patients (2015) (0)
P178 Prospective comparison of uPA/PAI-1, Ki-67 based molecular classification, Recurrence Score and clinical–pathological characteristics in hormone-receptor (HR) positive primary breast cancer: Pilot phase of the randomized WSG PlanB trial (2011) (0)
Abstract S01-03: The acute phase response identifies cancer patients with adverse outcomes from SARS-CoV-2 infection as quantified by the OnCovid Inflammatory Score (2021) (0)
New and future therapies for ER+ ABC (2011) (0)
BIOLOGICALLY BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE USE AMONG GERMAN BREAST CANCER PATIENTS UNDERGOING INTRAVENOUS OR ORAL ANTI-CANCER TREATMENT AND POTENTIALLY CLINICALLY RELEVANT INTERACTIONS (2021) (0)
Counseling and care: A Breast Cancer Awareness Training to improve participation and adherence to screening recommendations in women with a family history of breast cancer. (2009) (0)
The impact of breast care nurses on early-stage breast cancer patients' perception of quality of care: The results of a multilevel regression analysis. (2010) (0)
259 Implementation of Palliative Care in German Breast Centers ñ First Results of a National Questionnaire (2012) (0)
p53 Expression in Luminal Breast Cancer Correlates With TP53 Mutation and Primary Endocrine Resistance. (2023) (0)
Expression levels of ERBB2, ESR1, immune and proliferation signatures measured by RNASeq predict response to anti-HER2 treatment in the neoALTTO trial. (2015) (0)
Abstract P3-07-03: Endocrine sensitivity is decisive for patient outcome in small node-negative breast cancers (BC) (pT1a,b) – Results from the Munich Cancer Registry (2015) (0)
VinoMetro: phase II study of metronomic treatment with daily oral vinorelbine as first-line chemotherapy in patients with advanced/metastatic HR+/HER2-breast cancer resistant to endocrine therapy (2017) (0)
Prospective multicenter randomized phase III studies of weekly vs standard docetaxel (D2) plus doxorubicin (D4) for 1st line treatment of metastatic breast cancer (MBC) (2004) (0)
Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial. (2016) (0)
Abstract PS13-32: Hormone- and HER2 receptor change in non-pCR breast cancer specimens after neoadjuvant treatment (2021) (0)
Young breast cancer survivors-reproductive concerns, life satisfaction and cancer-specific distress (2016) (0)
Role of postoperative radiotherapy in reducing ipsilateral recurrence in DCIS: an observational study of 1048 cases (2018) (0)
Application of CDK4/6 inhibitors in advanced breast cancer: Effect of online education on clinician knowledge, competence and confidence (2018) (0)
Abstract P4-11-13: Cancer-specific distress, life satisfaction and parenting concerns in young breast cancer survivors (2016) (0)
St. Gallen/Vienna 2023: Optimization of Treatment for Patients with Primary Breast Cancer - a Brief Summary of the Consensus Discussion (2023) (0)
Life satisfaction and life quality in the elderly patient with breast cancer (2016) (0)
Correction: AGO Recommendations for the Surgical Therapy of the Axilla After Neoadjuvant Chemotherapy: 2021 Update (2021) (0)
Concordance and clinical impact of ER, PR, HER2 expression by local and central immunohistochemistry versus RT-PCR in HR+/HER2- early breast cancer (EBC): Results from the ADAPT trial. (2022) (0)
Abstract P6-07-05: Prognosis of 368 women with primary breast cancer during pregnancy: results from an international collaborative trial (2012) (0)
PO-0958: Neoadjuvant RT followed by mastectomy and immediate breast reconstruction: updated 5-years results (2020) (0)
A method for the treatment of proliferative diseases of mammary cells (2003) (0)
Toxicity data of the ADEBAR-Study multi centric Phase III-Study for the intake of cabs in the adjuvant therapy of the nodal-positive mamma carcinoma (2008) (0)
eLEcTRA trial: Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first line treatment in patients with hormone-receptor-positive, HER2-positive metastatic breast cancer (MBC) (2010) (0)
RE: Post-traumatic Stress as the Primary Cause for Cognitive Decline-Not the Whole Story, and Perhaps No Story at All. (2017) (0)
Abstract P3-11-06: Tumor Characteristics and Prognostic Factors in Nodal Positive Early Stage Breast Cancer of Obese Patients — Sub Analysis of the German ADEBAR Study (2010) (0)
Abstract OT2-02-02: MONARCH E: A phase 3 study of standard adjuvant endocrine therapy with or without abemaciclib in patients with high risk, node positive, hormone-receptor positive, human epidermal growth factor receptor 2-negative early-stage breast cancer (2020) (0)
539 The early integration of palliative care for breast cancer patients in the SOP breast cancer at the Cologne Bonn CIO (Center of interdisciplinary oncology) (2010) (0)
Heart sparing radiotherapy in breast cancer: the importance of baseline cardiac risks (2020) (0)
Recommendations from the society for diagnosis and therapy of haematological and oncological diseases Breast Cancer in Women (2018) (0)
Advanced Breast Cancer AGO Recommendations 2022 – Focus on ABC6 Consensus Fortgeschrittenes Mammakarzinom ABC6-Konsens im Fokus der AGO-Empfehlungen 2022 systemic therapy, (2022) (0)
Breast self examination training and counseling as motivation strategies for breast awareness and participation in breast cancer screening programs. (2006) (0)
Abstract P3-07-66: Efficacy and gene expression results from eribulin SOLTI1007 neoadjuvant study (2016) (0)
Editorial Board / Contents / Imprint / Contents of Forthcoming Issues (2016) (0)
Compliance and arthralgias in clinical therapy (COMPACT): Assessment of the incidence of arthralgia, therapy costs, and compliance in the first year of adjuvant anastrozole. (2012) (0)
P44 NNBC-3 Europe: A prospective clinical trial on riskestimation and optimization of adjuvant chemotherapy in node-negative breast cancer patients (2005) (0)
The eHealth service CANKADO to overcome nonadherence during oral self-medication. (2014) (0)
S-phase fraction and ploidy as independent prognostic criteria in primary breast cancer and their correlation to tumor-cell associated proteases (1993) (0)
Health-related quality of life in male breast cancer patients. (2010) (0)
Author Correction: Susceptibility to hormone-mediated cancer is reflected by different tick rates of the epithelial and general epigenetic clock (2022) (0)
Quality of life and subjective improvement of breast cancer related symptoms in advanced breast cancer – results of the anastrozol-surveillance-trial (2008) (0)
Abstract P6-13-01: Withdrawn (2018) (0)
5035 The patient's anastrozole compliance to therapy programme (PACT): evaluating the influence of a standardized information service on compliance in postmenopausal women with early breast cancer (2009) (0)
Markers for predicting the outcome of anthracycline treatment (2006) (0)
Comparison of hospital costs versus DRG reimbursement for treatment of febrile neutropenia during adjuvant CTX for primary breast cancer. (2010) (0)
[DNA flow cytometric analysis in primary breast cancer. S-phase and ploidy status as prognostic factors and their correlation to tumor-associated proteolytic factors]. (1993) (0)
Triple-negatives Mammakarzinom (2022) (0)
Abstract LB162: Evaluation of tumor immune biomarkers with pathologic complete response (pCR) in patients receiving atezolizumab + chemotherapy in early triple negative breast cancer (eTNBC): exploratory analyses from the IMpassion031 study (2021) (0)
[Development of a technique for isolation of intact tumor cells from fresh breast or ovarian cancer tissue. Use in analysis of tumor-associated proteolytic factors]. (1993) (0)
Trained Artificial Intelligence (AI) for Predicting Therapy Discontinuation Based on Patient Observations in Advanced Breast Cancer (2022) (0)
Contents, Vol. 29, Supplement 2, 1989 (1989) (0)
[Breast cancer in young women]. (2019) (0)
LBA2 Proposed biosimilar pegfilgrastim (LA-EP2006) compared with reference pegfilgrastim in Asian patients with breast cancer receiving myelotoxic chemotherapy: Pooled subgroup analysis of two randomized trials (2016) (0)
Cost-effectiveness of anastrozole versus tamoxifen as adjuvant therapy in early breast cancer (EBC) – a German health economic analysis. (2009) (0)
Use of nucleic acids of PITX2 to improve the treatment of proliferative disorders mammary cells (2003) (0)
Abstract P5-11-12: Quality of Life in the PACT-Programme (Patient's Anastrozole Compliance to Therapy Programme): Influence of a Standardized Information Service on Patient Satisfaction and Health Related Quality of Life in Postmenopausal Women with Early Breast Cancer (EBC) (2010) (0)
Preliminary Data from a Prospective Non-interventional Study to Characterize Real-World Treatment Patterns and Outcomes of Women with ER+/HER2-Advanced/Metastatic Breast Cancer (2017) (0)
Comparison of the prognostic significance of occult metastatic cells in the bone marrow (OMC-BM) and HER2-status in patients with stage I–III breast cancer (BC) (2001) (0)
Results of Falsodex IPEP in the use of Fulvestrant in everyday conditions - Investigation of the safety, effectiveness,tolerance and acceptance of Fulvestrant in postmenopausal breast cancer (2014) (0)
Contents, Vol. 33, Supplement 1, 1993 (1993) (0)
Is tumorbiological risk assessment realistic in node-negative breast cancer? Study progress and quality assurance of the multicenter trial NNBC 3-Europe (2008) (0)
BP52 IS THERE A DIFFERENT TREATMENT RESPONSE BETWEEN VISCERAL AND NON-VISCERAL METASTATIC BREAST CANCER: A SYSTEMATIC LITERATURE REVIEW OF REGISTRATION TRIALS (2015) (0)
Gallen-Konsensuskonferenz ( Wien 2017 ) Initial Treatment of Patients with Primary Breast Cancer : Evidence , Controversies , Consensus Spectrum of Opinion of German Specialists at the 15 th International St . Gallen Breast Cancer Conference ( Vienna 2017 ) (2017) (0)
Contents, Vol. 33, Supplement 1, 1993 (1993) (0)
Efficacy and gene expression results from SOLTI1007, a phase II study evaluating neoadjuvant eribulin in hormone receptor (HR)-positive/HER2-negative breast cancer (2016) (0)
Subject Index Vol. 33, 2010 (2010) (0)
55P Molecular risk factors for distant metastases in premenopausal patients with HR+/HER2- EBC (2021) (0)
ADAPTcycle: Adjuvant dynamic marker-adjusted personalized therapy comparing endocrine therapy plus ribociclib versus chemotherapy in intermediate-risk HR+/HER2- early breast cancer. (2019) (0)
Corrigendum to “Efficacy + safety of palbociclib (P) in patients (pts) ≤50 y with hormone receptor‒positive (HR+)/human epidermal growth factor receptor 2‒negative (HER2–) advanced breast cancer (ABC): Subgroup analysis of 2 randomized phase 3 studies” [Breast 41S1 (2018) S11–12] (2020) (0)
Abstract P2-05-04: Deregulation of A-to-I RNA editing is associated with poor prognosis in HER2+ breast cancers in the neoALTTO trial (2017) (0)
Abstract OT2-2-01: tnAcity: A phase II/III trial ofnab-paclitaxel (nab-P) plus either gemcitabine (Gem) or carboplatin (Carbo) vs Gem/Carbo as first-line treatment for patients with triple-negative metastatic breast cancer (TNMBC): (2015) (0)
Contribution of the Prosigna® (PAM50) Gene Signature Assay as a New-generation Genomic Test for Treatment Decision-making in Early Breast Cancer (2015) (0)
[Prognostic value of tumor cells in bone marrow in breast cancer]. (1993) (0)
Contents Vol. 24, 2003 (2004) (0)
Patient's Anastrozole Compliance to Therapy Programme (PACT): Influence of the addition of a standardized information and reminder service on compliance in comparison to standard clinical care alone in women with early-stage breast cancer (2008) (0)
First Results from the “Patient's Anastrozole Compliance to Therapy Programme” (PACT) Evaluating the Impact of a Standardized Information Service on Compliance in Postmenopausal Women with Early Breast Cancer (EBC) Receiving Adjuvant Endocrine Therapy. (2009) (0)
E12. uPA and PAI-1 in primary breast cancer: from bench to bedside (2004) (0)
0069 Prognostic factors upa and PAI-1: Feasibility and validity of determination in clinical routine (2009) (0)
Author Correction: Susceptibility to hormone-mediated cancer is reflected by different tick rates of the epithelial and general epigenetic clock (2022) (0)
Recommendations from the society for diagnosis and therapy of haematological and oncological diseases Guideline Breast Cancer in Women (2016) (0)
Adjuvant dynamic marker-adjusted personalized therapy comparing endocrine therapy plus ribociclib versus chemotherapy in intermediate-risk HR+/HER2- early breast cancer: ADAPTcycle. (2022) (0)
Counseling of breast cancer patients at primary therapy by breast cancer survivors: Experiences with a pilot project (2004) (0)
A trial to improve risk estimation and risk adapted adjuvant chemotherapy in node-negative breast cancer patients: NNBC-3 Europe (2003) (0)
P45 Tumorbiological factors (uPA, PAI-1) as selection criteria for adjuvant chemotherapy in axillary node-negative breast cancer patients (1998) (0)
Patients with Recurrent Breast Cancer Aminotransferase with Response to Endocrine Therapy in Association of DNA Methylation of Phosphoserine (2005) (0)
Abstract PD3-01: Neoadjuvant pembrolizumab + chemotherapy vs placebo + chemotherapy followed by adjuvant pembrolizumab vs placebo for early TNBC: Post hoc analysis of adjuvant radiation therapy in the phase 3 KEYNOTE-522 study (2023) (0)
Incremental costs of chemotherapy – Pharmacoeconomic results from the prospective adjuvant WSG-AGO Intergroup EC-DOC trial comparing an anthracycline-docetaxel sequence to CMF in node-positive breast cancer (2008) (0)
Gene signatures in patients with early breast cancer and relapse despite pathologic complete response (2022) (0)
Abstract PS2-02: Prognostic relevance of the HER2 status of circulating tumor cells in metastatic breast cancer patients screened for participation in the DETECT study program (2021) (0)
The prognostic impact of Plasminogen Activator Inhibitor Typel (PAI-I) and Urokinase-type Plasminogen Aktivator (uPA) concentrations in axillary lymph node metastasis in patients with primary breast cancer (2008) (0)
3rd international, interdisciplinary symposium “Physical activity in Oncology” at the German Sport University Cologne from May 11th ‐ 12th 2012 – Abstracts (2012) (0)
24P Consensus on the utility of breast cancer multigene signatures in routine clinical practice among European breast cancer clinicians: The PROCURE project (2021) (0)
Influence of patient and tumor characteristics on therapy persistence with letrozole in postmenopausal women with advanced breast cancer: results of the prospective observational EvAluate-TM study (2019) (0)
Impact of PIK3CA mutation status on immune marker response and pCR in the WSG-ADAPT HER2+/HR+ phase II trial. (2018) (0)
Reply to K. Hashimoto and A. Shimomura. (2021) (0)
260 Primary Tumor in Breast Cancer and Its Phenotype in Positive Lymph Nodes and Later Disease Recurrence (metastatic Breast Cancer): Results of the PRIMET-trial (WSG/DETECT) (2012) (0)
EP-1319: Long-term results of partial-breast-IORT or IORT-boost: a 10-year mono-institutional experience (2018) (0)
Abstract OT3-14-01: GERA: A health economic trial to analyze the impact of ehealth in breast cancer care (2020) (0)
PP 30 Prospective comparison of Recurrence Score, uPA/PAI-1, central grade and molecular subtyping in early breast cancer: first results from the WSG-Plan B trial (interim analysis) (2011) (0)
Hormone receptor discordance between local and central pathology with RT-PCR analysis: Results from multicenter Phase III WSG-PlanB trial. (2015) (0)
Diversity, inclusion, and patient (pt)-centricity in the randomized, double-blind, phase III ASTEFANIA study of ado-trastuzumab emtansine (T-DM1) ± atezolizumab in pts with HER2-positive early breast cancer (EBC) with residual invasive disease after preoperative chemotherapy and anti-HER2 therapy. (2022) (0)
Impact of uPA/PAI-1 and disseminated cytokeratin-positive cells in breast cancer (2019) (0)
External and internal assurance of the determination of the prognostic factors uPA and PAI-1 for the ongoing NNBC 3-Europe trial (2008) (0)
Dislocation of Intravenous Port Systems – Three Case Reports (2009) (0)
Combination of urokinase-type plasminogen activator (uPA) and its type 1 inhibitor (PAI-1) has not only prognostic but also predictive impact in primary breast cancer (2003) (0)
Validity of DNA-methylation marker PITX2 to predict risk of recurrence in lymph node-negative hormone receptor-positive breast cancer patients: a transfer study. (2005) (0)
Magnetic resonance imaging and ultrasound for prediction of residual tumor size in early breast cancer within the ADAPT subtrials (2021) (0)
Results of the German IPEP study evaluating the tolerability, efficacy, and acceptance of fulvestrant (Faslodex(r)) under routine clinical conditions in advanced breast cancer (2008) (0)
ER+, HER2- advanced breast cancer treated with taselisib and fulvestrant: genomic landscape and associated clinical outcomes. (2023) (0)
Abstract 1998: Predictive and prognostic role of T- and B-cell receptor repertoire in HER2-positive breast cancer: An analysis of the NeoALTTO clinical trial (2020) (0)
IN9 The management of triple negative breast cancer (2014) (0)
Participation in phase III ADEBAR: evaluating the role of adjuvant docetaxel in high-risk breast cancer patients improves treatment strategies and individual patient care in recruiting centers (2004) (0)
Contents Vol. 8, 2013 (2013) (0)
Evaluation and optimization of treatment for patients with metastatic breast cancer and receiving CDK4/6-inhibitors (2022) (0)
Abstract PS11-16: Rare patients in routine care: Treatment and outcome in advanced invasive lobular breast cancer in the prospective German research platform OPAL (2021) (0)
Systematic comparison of tumor phenotype in primary breast cancer versus corresponding lymph nodes and disease recurrences: Results of the retrospective multicenter WSG/DETECT PriMet study. (2011) (0)
HER2-Positive Breast Cancer: Adjuvant and Neoadjuvant Therapy (2013) (0)
[P2-09-01] T-cell receptor beta chain variable region (TRBV) expression patterns predict response to combined trastuzumab/lapatinib treatment in the NeoALTTO/BIG-1-06 trial (2018) (0)
116TiPMONALEESA-7: a phase III, randomized, double-blind, placebo-controlled study of ribociclib (LEE011) combined with standard first-line endocrine therapy (ET) for the treatment of premenopausal women with HR + , HER2– advanced breast cancer (aBC) (2015) (0)
Subjective assessment of breast cancer related symptoms, activity levels and quality of life of patients with metastatic breast cancer under treatment with Anastrozole (2006) (0)
Abstract P3-14-01: Features of neoadjuvant and adjuvant chemotherapy in breast cancer – A population-based study on 39404 patients (2013) (0)
9 INVITED proper biochemical target evaluation - which types of clinical trials are needed for validation? (2006) (0)
Genotyping of Caucasian individuals in the dihydropyrimidine dehydrogenase gene (2005) (0)
312TiPVinoMetro: Phase II study of metronomic daily oral vinorelbine as first-line chemotherapy in advanced/metastatic hormone receptor positive (HR+)/human epidermal growth factor receptor 2 negative (HER2-) breast cancer resistant to endocrine therapy (2017) (0)
More power than knowledge? - The molecular therapy of breast cancer: Prospects of translational medicine in Germany (2008) (0)
Capecitabine (X) in the first-line treatment of metastatic breast cancer (MBC). (2011) (0)
Efficacy + safety of palbociclib (P) in patients (pts) ≤50 y with hormone receptor‒positive (HR+)/human epidermal growth factor receptor 2‒negative (HER2–) advanced breast cancer (ABC): subgroup analysis of 2 randomized phase 3 studies (2018) (0)
ADAPTcycle – adjuvant dynamic marker-adjusted personalized therapy comparing endocrine therapy plus ribociclib versus chemotherapy in intermediate risk HR+/HER2- early breast cancer (2019) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Nadia Harbeck?

Nadia Harbeck is affiliated with the following schools:

University of Calgary
Humboldt University of Berlin
University of Cologne
KU Leuven
Ludwig Maximilian University of Munich
Fukushima Medical University
University of Michigan
University of California, Los Angeles
National Taiwan University
Technical University of Munich
Kyoto University
Seoul National University
Université libre de Bruxelles
Yale University
Hannover Medical School
University of Edinburgh
University of Zurich

Nadia Harbeck's Academic­Influence.com Rankings

Why Is Nadia Harbeck Influential?

Nadia Harbeck's Published Works

Published Works

What Schools Are Affiliated With Nadia Harbeck?

Nadia Harbeck's AcademicInfluence.com Rankings